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Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treat-
ment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromo-
endoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early 
gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before 
the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be per-
formed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully 
made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular 
invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopi-
cally resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for en-
doscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encom-
passes endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal 
cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected. (Intest Res 2021;19:127-157)
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INTRODUCTION
Endoscopic resection is a minimally invasive procedure for 
the treatment of early gastrointestinal cancers including 
esophageal, gastric, and colorectal cancers.1 In South Korea, 
the widespread use of upper gastrointestinal and colorectal 
endoscopies for screening purposes has increased the rate of 
early diagnosis of gastrointestinal cancers and, subsequently, 
the number of endoscopic resections performed for early gas-
trointestinal cancers.2,3 The popularity of endoscopic submu-
cosal dissection (ESD) has rapidly increased with over thou-
sands of ESD procedures performed per year as the proce-
dure allows the en bloc resection of a lesion regardless of its 
size and location.3,4 ESD was first introduced in South Korea 
in 1999 and has been widely accepted as a treatment method 
for early gastric cancer since 2003. It was performed in 45 ter-
tiary medical institutions in 2014 and is being performed in 
44% of the total 287 general hospitals in South Korea.5
Endoscopic resection does not require general anesthesia, 
has fast recovery time relative to the extent of resection, re-
quires a short hospital stay, and is cost-friendly.6 However, 
since the procedure only resects primary local lesions and not 
the lymph nodes, it is important to screen patients for early 
gastrointestinal cancer without a possibility of lymph node 
metastasis before endoscopic resection.1,7,8 Additionally, even 
if endoscopic resection of a local lesion is successful, surgical 
resection must still be considered to minimize the possibility 
of cancer recurrence and metastasis when histopathological 
risk factors associated with cancer recurrence in the lymph 
nodes are detected in the endoscopic resection specimen. 
High-resolution endoscopy, image-enhanced endoscopy, 
chromoscopy, magnification endoscopy, endoscopic ultra-
sound, and computed tomography (CT) are used in making 
the clinical decision of whether to perform endoscopic resec-
tions,9-15 and models have been developed that can predict 
patients with high likelihoods of lymph node metastasis.1,7,8,16,17 
Evidence-based guidelines published from other countries 
help clinicians with decision-making regarding the examina-
tion and treatment of gastrointestinal cancers.1 However, since 
the incidence of gastrointestinal cancers and available medi-
cal resources vary greatly depending on the target organs 
(esophagus, stomach, and colon), countries, and regions, di-
rect application of foreign guidelines to the medical situations 
of South Korea would be inadequate. South Korea still has no 
clinical practice guidelines for endoscopic resection of early 
gastrointestinal cancers despite the high need for it, forcing 
physicians to refer to foreign clinical practice guidelines or re-
view domestic literatures and apply their results in clinical 
practice. The present clinical practice guideline comprehen-
sively reviews studies on endoscopic resection of early gastro-
intestinal cancers conducted in and outside Korea and pro-
poses recommendations for the examination and treatment 
of early gastrointestinal cancers after considering the epide-
miological and clinical characteristics of early gastrointestinal 
cancers and medical environments in the country. This guide-
line consists of three sections, each discussing superficial 
esophageal squamous cell carcinoma (SESCC), early gastric 
cancer, and early colorectal cancer, and will be subject to revi-
sions and modifications based on future research findings. 
METHODS
1.  Purpose and Scope of Developing Clinical Practice 
Guideline
We aimed to develop a treatment guideline for endoscopic re-
section of early gastrointestinal cancers that caters to the cur-
rent medical situations in Korea and can be used in clinical 
settings. The target population for this guideline included male 
and female adults with SESCC, early gastric cancer, and early 
colorectal cancer requiring endoscopic resection. The users of 
this clinical guideline are gastroenterologists who perform 
gastrointestinal endoscopy in primary, secondary, and tertiary 
medical institutions. To facilitate the understanding of gastro-
enterologists, the definitions of terms regarding endoscopic 
resection were presented in Table 1. The purpose of the guide-
line is to help these physicians make decisions regarding pa-
tient diagnosis, preoperative evaluation, method of resection, 
and postoperative management. It also aims to guide resident 
physicians and hospital employees in these aspects and pro-
vide patients and healthy persons with realistic and standard 
medical information.
2.  Formation of the Clinical Practice Guideline Com-
mittee and Development Process
The Clinical Practice Guideline Committee consisted of the 
president (Hoon Jai Chun), congress chairman (Soo Teik Lee), 
and committee members of Korean Society of Gastrointesti-
nal Endoscopy (KSGE) in November 2017. The members of 
the committee established a development strategy, elected a 
director of clinical practice guideline project, and reviewed 
and approved budgets regarding the project. In addition, they 
reviewed proposed recommendations and ensured editorial 
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independence and participation of all involved parties in the 
guideline editing process. The Clinical Practice Guideline 
Committee in January, 2020 (Joo Young Cho, the president 
and Chan Guk Park, the congress chairman) reviewed the fi-
nal version of guideline and approved its publication.
The Clinical Practice Guideline Committee formed the KSGE 
Task Force on Clinical Practice Guideline, which directed the 
development of the clinical practice guideline for endoscopic 
resection of early gastrointestinal cancers. For multidisciplinary 
development of the clinical practice guideline, Jeong-Sik Byeon, 
a gastroenterologist and member of KSGE, was appointed as 
the director of the KSGE Task Force on Clinical Practice Guide-
line along with the recommended medical experts of KSGE 
(Jong Wook Kim, Jie-Hyun Kim, Ji Hyun Kim, Yang Won Min, 
Chan Hyuk Park, Si Hyung Lee, and Jong Yeul Lee), the Korean 
Society of Gastroenterology (Jung Ho Bae, Dong-Hoon Yang, 
Hyunsoo Chung, and Kee Don Choi), the Korean College of 
Helicobacter and Upper Gastrointestinal Research (Jun Chul 
Park and Hyuk Lee), the Korean Association for the Study of 
Intestinal Diseases (Min-Seob Kwak), the Korean Society of 
Gastrointestinal Cancer (Bun Kim and Hyun Jung Lee), and 
the Korean Society of Pathologists (Hye Seung Lee) as mem-
bers of the KSGE Task Force. Additionally, two experts (Dong-
Ah Park and Miyoung Choi) of clinical practice guideline de-
velopment from the National Evidence-based Healthcare Col-
laborating Agency participated in the guideline development. 
Three sub-committees were formed for each gastrointestinal 
cancer—SESCC (team leader: Kee Don Choi), early gastric 
cancer (team leader: Jong Yeul Lee), and early colorectal can-
cer (Dong-Hoon Yang)—to ensure systematic guideline devel-
opment. The sub-committees selected key questions for the 
guideline, conducted a literature search, derived recommen-
dations, and wrote and edited the first draft of the guideline.
To maintain consistency in guideline development among 
the sub-committees, the KSGE Task Force on Clinical Practice 
Guideline held four meetings since December 22, 2017. The 
Task Force also held two workshops to establish a methodolo-
gy for guideline development and review the development 
process (March 12, 2018 and November 10, 2018). These 
workshops were accompanied by an education session on the 
methods of guideline development, grading of scientific evi-
dence and recommendations, and achievement of recom-
mendation consensus. The Task Force chose the de novo 
guideline development approach. The sub-committees for 
guideline development developed the clinical practice guide-
line through online and in-person meetings.
3. Selection of Key Questions
Selection criteria were established, and a questionnaire was 
formed through the PICO process wherein key questions to 
be included in the clinical practice guideline were derived. P 
(population) represents patients with SESCC, early gastric 
cancer, and early colorectal cancer; I (intervention) represents 
interventions including diagnostic and treatment methods; C 
(comparison) includes patient groups for comparison be-
tween specific intervention methods; and O (outcome) repre-
sents the usefulness of diagnosis or treatment outcome. The 
PICO processes are presented in Supplementary Material 1. 
The members of the sub-committees for guideline develop-
ment gathered questionnaires containing key questions and 
rated the importance of each question to determine the ques-
tions to be included in the clinical practice guideline. Studies 
were excluded if any of the following was noted: (1) the stud-
ies did not involve human subjects or the target patients of the 
guideline’s key questions; (2) the studies did not conduct an 
intervention related to the key questions and an intervention 
for comparison; (3) the studies were review articles, case re-
ports or abstracts only; (4) the studies were not published in 
English or Korean; and (5) the studies’ original copies could 
not be found. In case where ≥ 2 studies used the same groups 
of subjects, the smaller studies were excluded.
4. Literature Search and Selection
A literature search was conducted using the MEDLINE, EM-
Table 1. Definition of Terms Related to Endoscopic Resection
Term Definition
En bloc resection Resection of a tumor in one piece without visible residual tumor
Complete resection Resection of a tumor without histological evidence of tumor cell involvement on the lateral and vertical resection margins
Curative resection Resection of an early gastrointestinal cancer, which is considered curative based on complete resection and minimal to no 
risk of lymph node metastasis
The criteria for curative resection are different according to the type of cancers (early esophageal, gastric and colorectal 
cancers)
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BASE, Cochrane Library, KoreaMed, and the Guideline Inter-
national Network in August 2018 by Miyoung Choi, a resear-
cher from the National Evidence-based Healthcare Collabo-
rating Agency. Keywords related to esophageal cancer ((“eso-
phageal” OR “esophagus” OR “oesophageal” OR “oesophagus” 
OR “gullet”) AND (“cancer$” OR “tumo?r” OR “carcinoma$” 
OR “adenocarcinoma$” OR “neoplas$”)), gastric cancer ((“sto-
mach” OR “gastric”) AND (“cancer$” OR “tumo?r” OR “carcino-
ma$” OR “adenocarcinoma$” OR “neoplas$”)), colorectal can-
cer ((“colon$” OR “rectum” OR “colorectal” OR “rectal”) AND 
(“polyp$” OR “cancer” OR “adenoma$” OR “adenocarcino$” 
OR “carcino$” OR “tumo?r”)), and endoscopic resection ((“en-
doscop$”) AND (“dissection” OR “resection” OR “treat$” OR 
“ESD”)) were used. Different keywords or different combina-
tions of keywords were also used based on the key questions. 
Duplicate articles were removed. Two committee members 
were assigned to the key questions, and they independently 
selected articles according to the inclusion and exclusion cri-
teria. They first removed articles irrelevant to the guideline de-
velopment based on titles and abstracts and then reviewed 
the entire content of the remaining articles for further screen-
ing. Any disagreements between the two members were re-
solved through negotiations. In case they did not reach a con-
sensus, the team leader of the corresponding sub-committee 
made the final decision. The flowchart showing the searching 
process is shown in Supplementary Material 2.
5.  Bias Assessment and Summary of Evidence and Rec-
ommendation Grade
The validity of the selected articles that would form the basis 
of the clinical practice guideline was assessed using systemat-
ic methods. The revised Cochrane Risk of Bias Tool was used 
to evaluate randomized comparative studies,18,19 and RoBANS 
2.0 and Newcastle–Ottawa assessment scale were used to 
evaluate nonrandomized studies.20 The QUADAS-2 (Quality 
Assessment of Diagnostic Accuracy Studies-2) tool was used 
for diagnostic studies.21 The GRADE (Grading of Recommen-
dations Assessment, Development and Evaluation) method 
was used to present summaries of evidence.22 Although, by 
default, randomized comparative studies have high levels of 
evidence, and observational studies low levels of evidence, a 
study’s final level of evidence was determined as high, moder-
ate, low, or very low based on various factors affecting the 
quality of research.
The grade of recommendation was determined as strong or 
weak based on the balance between positive and negative ef-
fects of the recommendation, quality of evidence, values, and 
preferences. Strong recommendations are recommended to 
most patients since the recommendations have more positive 
than negative effects, are supported by high-quality evidence, 
are highly valuable, and are more strongly preferred than oth-
er interventions. Weak recommendations are also beneficial 
for many patients although they have relatively small positive 
effects that are supported by weak evidence. Alternative inter-
Table 2. Summary and Strength of Recommendations for SESCC
Statement E1: We recommend endoscopic resection for SESCC without distant or lymph node metastasis, excluding those with obvious submucosal 
invasion (Grade of recommendation: strong, Level of evidence: moderate).
Statement E2: We recommend Lugol chromoendoscopy and/or image-enhanced endoscopy to define the extent of lesion before endoscopic 
treatment of SESCC (Grade of recommendation: strong, Level of evidence: moderate).
Statement E3: We recommend endoscopic ultrasound to define the stage of SESCC before endoscopic treatment (Grade of recommendation: strong, 
Level of evidence: moderate).
Statement E4: We suggest magnifying endoscopy with narrow band imaging for SESCC to assess the depth of invasion before endoscopic treatment 
(Grade of recommendation: weak, Level of evidence: low).
Statement E5: We recommend endoscopic submucosal dissection rather than endoscopic mucosal resection for en bloc and curative resection of 
SESCC confined to the mucosa (Grade of recommendation: strong, Level of evidence: moderate).
Statement E6: We recommend oral steroid or local steroid injection therapy for patients who develop mucosal defects in >75% of the esophageal 
circumference after endoscopic submucosal dissection to prevent esophageal stricture (Grade of recommendation: strong, Level of 
evidence: moderate).
Statement E7: No additional treatment is recommended after en bloc complete resection of SESCC invading no more than the lamina propria with no 
lymphovascular invasion because of a very low risk of lymph node metastasis (Grade of recommendation: strong, Level of evidence: 
moderate). As the risk of lymph node metastasis of a tumor invading into the muscularis mucosa without lymphovascular invasion 
is low, a close follow-up after en bloc complete endoscopic resection can be considered without additional treatment (Grade of 
recommendation: weak, Level of evidence: low). In case of a tumor with submucosal invasion, lymphovascular invasion, and/or positive 
vertical resection margin, additional treatment is recommended (Grade of recommendation: strong, Level of evidence: moderate).
SESCC, superficial esophageal squamous cell carcinoma.
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vention method may be chosen instead of the weakly recom-
mended intervention depending on the health professionals’ 
values and preferences. Tables 2-4 summarize the recommen-
dations with their grades of recommendation and levels of evi-
dence, respectively.
6. Review and Approval
An editorial committee consisting of 29 members of KSGE 
Steering Committee, 14 members from the Insurance Com-
mittee, and 15 members from the Research Group for Endo-
scopic Submucosal Dissection was formed in August, 2019. 
The members evaluated the first draft of the guideline using 
open-ended questions. The draft was revised by the KSGE 
Task Force on Clinical Practice Guideline and re-evaluated by 
the editorial committee to ensure information balance and 
guideline completion. For an external review of the guideline, 
a public meeting in which 38 gastrointestinal endoscopy ex-
perts participated was held on August 18, 2019 during the 61st 
seminar of KSGE in which doctors and nurses from all over 
the country gathered. Opinions about the guideline were 
shared during the public meeting and the final draft of guide-
line was made after its revision based on discussion during 
the public meeting.
7.  Provision of Clinical Practice Guideline and Plans 
for Future Updates
For wide provision and distribution of the clinical practice 
guideline, we plan to publish the guideline in Intestinal Re-
search, Clinical Endoscopy, the Korean Journal of Gastroenter-
ology, the Korean Journal of Helicobacter and Upper Gastroin-
Table 3. Summary and Strength of Recommendations for Early Gastric Cancer
Statement G1: We recommend chromoendoscopy/image-enhanced endoscopy to determine the extent of lesion before endoscopic treatment of 
early gastric cancer (Grade of recommendation: strong, Level of evidence: moderate).
Statement G2: Endoscopic ultrasonography before endoscopic resection of early gastric cancer may be helpful in determining the depth of invasion 
in some patients with early gastric cancer (Grade of recommendation: weak, Level of evidence: moderate).
Statement G3: We recommend endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma 
meeting endoscopically estimated tumor size ≤2 cm and endoscopically suspected mucosal cancer without ulcer (Grade of 
recommendation: strong, Level of evidence: moderate).
Statement G4: We suggest endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma 
meeting the following endoscopic findings: 1) mucosal cancer >2 cm without ulcer, or 2) mucosal cancer ≤3 cm with ulcer (Grade of 
recommendation: weak, Level of evidence: moderate).
Statement G5: We suggest endoscopic resection for poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, and signet ring cell 
carcinoma meeting the following endoscopic findings: endoscopically estimated tumor size ≤2 cm, endoscopically mucosal cancer, 
and no ulcer in the tumor (Grade of recommendation: weak, Level of evidence: low).
Statement G6: We recommend prophylactic hemostasis of visible vessels on the post-resection ulcer caused by endoscopic resection of early gastric 
cancer to lower the risk of delayed bleeding (Grade of recommendation: strong, Level of evidence: low).
Statement G7: We recommend proton pump inhibitors to decrease the risk of symptoms and complications associated with iatrogenic ulcers caused 
by endoscopic resection of early gastric cancer (Grade of recommendation: strong, Level of evidence: high).
Statement G8: We recommend endoscopic closure as the first treatment option for perforation that occurred during endoscopic resection of early 
gastric cancer (Grade of recommendation: strong, Level of evidence: low).
Statement G9: We recommend surgical gastrectomy if histopathological evaluation after endoscopic resection of early gastric cancer meets the 
criteria for non-curative resection. An exception applies if cancer invasion is observed at the horizontal resection margin only (Grade 
of recommendation: strong, Level of evidence: moderate).
Statement G10: We recommend additional endoscopic management rather than surgical gastrectomy if histopathological evaluation of endoscopically 
resected early gastric cancer specimen shows positive involvement at the horizontal resection margin without any other findings 
compatible with non-curative resection (Grade of recommendation: strong, Level of evidence: moderate).
Statement G11: We recommend Helicobacter pylori eradication treatment after endoscopic resection of early gastric cancer in H. pylori-infected 
patients (Grade of recommendation: strong, Level of evidence: high).
Statement G12: We recommend regular surveillance endoscopy every 6–12 months for patients who have had curative endoscopic resection of early 
gastric cancer based on absolute or expanded criteria for early detection of metachronous gastric cancer (Grade of recommendation: 
strong, Level of evidence: low).
Statement G13: We suggest regular abdominopelvic computed tomography scan of 6- and 12-month interval for detection of extra-gastric recurrence 
after curative endoscopic resection of early gastric cancer based on absolute and expanded criteria (Grade of recommendation: weak, 
Level of evidence: low).
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testinal Research, and Journal of Digestive Cancer Reports. We 
will also upload the guideline on the website of KSGE and 
submit it to the Korean Medical Guideline Information Center. 
Because we expect slow distribution of guidelines among en-
doscopists through databases for clinical practice guidelines, 
KSGE, the main institution for developing the guideline, will 
send out the guideline for free via various routes including 
emails and will actively advertise the guideline in academic 
conferences, seminars, and workshops. Current recommen-
dations in the clinical practice guideline are based on research 
conducted up to date and will be subject to revisions based on 
future findings.
8. Limitations
The most critical limitation of this clinical practice guideline is 
the insufficiency of data pertaining to Koreans. Data from for-
eign countries cannot be directly used to develop a guideline 
for the Korean population since the epidemiological and clini-
cal characteristics of early gastrointestinal cancers differ be-
tween Korean and foreign populations. In addition, this clini-
cal practice guideline does not aim to provide an absolute 
treatment standard that physicians should use to manage pa-
tients in real clinical settings but aims to help physicians make 
evidence-based clinical judgments with regard to the treat-
ment of early gastrointestinal cancers. A physician must ex-
amine various clinical aspects of a patient before making any 
treatment decisions. This clinical practice guideline shall not 
be used to restrict medical practice of physicians, as health in-
surance criteria, or to make legal judgments regarding treat-
ments performed on a particular patient.
9. Editorial Independence
This clinical practice guideline is a project selected and fund-
ed by KSGE. KSGE did not influence the process of guideline 
development in any manner. All parties involved in the guide-
line development had no conflict of interests regarding the 
guideline development.
SUPERFICIAL ESOPHAGEAL SQUAMOUS CELL 
CARCINOMA
Statement E1
We recommend endoscopic resection for SESCC without 
distant or lymph node metastasis, excluding those with ob-
vious submucosal invasion (Grade of recommendation: 
strong, Level of evidence: moderate).
SESCC is squamous cell carcinoma of the esophagus that is 
localized to the mucosa or submucosa. SESCC without dis-
tant metastasis and with a low risk of lymph node metastasis is 
a good target of endoscopic resection. Although endoscopic 
resection of SESCC can conserve the esophagus, it is impor-
tant to carefully select patients who will receive the procedure 
since there is still a possibility of lymph node metastasis. The 
National Comprehensive Cancer Network guidelines recom-
mend endoscopic resection for SESCC localized to the mu-
cosa and esophagectomy in the presence of submucosal inva-
sion.23 The Japan Esophageal Society defines mucosal cancer 
invading only as deep as the lamina propria as an absolute 
indication for endoscopic resection as the cancer rarely me-
tastasizes to the lymph nodes.17 The European Society of Gas-
trointestinal Endoscopy (ESGE) defines esophageal cancer 
invading the lamina propria without lymph node metastasis 
as an absolute indication for endoscopic resection.1 Thus, the 
depth of invasion of SESCC must be accurately determined 
using endoscopy, endoscopic ultrasound, and magnifying en-
doscopy with narrow band imaging (NBI) before performing 
endoscopic resection of SESCC.24-28 However, the evaluation 
of invasion depth is not perfectly accurate. Therefore, it is ad-
Table 4. Summary and Strength of Recommendations for Early Colorectal Cancer
Statement C1: Poor histologic types (poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma), deep submucosal 
invasion, lymphovascular invasion, and intermediate-to-high-grade tumor budding at the site of deepest invasion are risk factors of 
lymph node metastasis in early colorectal cancer (Grade of recommendation: strong, Level of evidence: moderate).
Statement C2: Endoscopic resection of submucosal colorectal cancer with a high risk of lymph node metastasis has a higher recurrence rate than 
surgical resection. Therefore, we recommend additional surgery if histological signs after endoscopic resection suggest a high risk of 
lymph node metastasis (Grade of recommendation: strong, Level of evidence: high).
Statement C3: We recommend endoscopic assessment of pit patterns and vascular patterns to estimate the depth of submucosal invasion before 
endoscopic resection of early colorectal cancer (Grade of recommendation: strong, Level of evidence: high).
Statement C4: En bloc and histologically complete resection should be achieved for endoscopic treatment of a suspected or established early colorectal 
cancer. We recommend endoscopic submucosal dissection for the treatment of endoscopically resectable early colorectal cancer which 
cannot be resected en bloc using endoscopic mucosal resection technique (Grade of recommendation: strong, Level of evidence: moderate).
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visable to perform endoscopic resection instead of esophagec-
tomy to avoid unnecessary operations when there is no obvi-
ous submucosal invasion because esophagectomy has high 
morbidities and mortalities.29-31 Recent Korean studies report 
no significant difference in long-term survival between pa-
tients with SESCC without obvious submucosal invasion who 
underwent endoscopic resection as their first treatment and 
those who underwent esophagectomy, and the rate of postop-
erative complications was significantly higher in the operated 
patients.32 This may be because additional operations lowered 
the risk of recurrence following non-curative endoscopic re-
section. A Chinese study also reported no significant difference 
in survival rates between patients with SESCC who under-
went endoscopic resection and those who underwent surgical 
resection and reported a lower incidence of treatment-related 
complications in the former group.33 These results show that 
performing endoscopic resection prior to a surgical resection 
of SESCC without obvious submucosal invasion may be an ef-
fective treatment strategy.
Statement E2
We recommend Lugol chromoendoscopy and/or image-
enhanced endoscopy to define the extent of lesion before 
endoscopic treatment of SESCC (Grade of recommenda-
tion: strong, Level of evidence: moderate). 
SESCC manifests as erythematous lesions, subtle discolor-
ation, or nodules. In addition, synchronous SESCC lesions of 
various sizes are not rare, which are difficult to be distin-
guished from noncancerous lesions only by white light endos-
copy. Therefore, accurate measurement of the size and hori-
zontal border of these lesions is challenging. Lugol chromoen-
doscopy, which applies the fact that the keratin layer of the 
mucosa is destroyed by the cancer, is the most effective chro-
moendoscopy to identify the SESCC lesions. The normal 
esophageal mucosa turns dark brown when sprayed with Lu-
gol’s solution, whereas the mucosa affected by SESCC exhibits 
a “pink-color sign.” That is, the mucosa remains light brown 
and turns pink 2–3 minutes after being sprayed with the solu-
tion.34 Studies evaluating the efficacy of Lugol chromoendos-
copy in diagnosing lesions suggestive of SESCC in white light 
endoscopy reported Lugol chromoendoscopy to be 73.8%–
93.4% accurate in differentiating high-grade adenoma and 
SESCC from low-grade adenoma and noncancerous le-
sions.34,35 Thus, Lugol chromoendoscopy effectively assesses 
the horizontal border of SESCC before endoscopic resection.
Image-enhanced endoscopy is a quick process that causes 
no inflammation around SESCC lesions unlike Lugol chromo-
endoscopy. Image-enhanced endoscopy with NBI is the most 
widely studied image-enhanced endoscopy technique.36 In a 
study of 90 patients with high-grade adenoma and SESCC, the 
accuracy of image-enhanced endoscopy with NBI was signifi-
cantly higher than that of white light endoscopy (92% vs. 
67.8%), and was similar to that of Lugol chromoendoscopy 
(92% vs. 93.4%).37 In a prospective study that compared the di-
agnostic accuracy of detecting SESCC between Lugol chro-
moendoscopy and image-enhanced endoscopy with NBI in 
303 patients with high risk of SESCC, the accuracy of the im-
age-enhanced endoscopy with NBI was 91.2%, which was not 
inferior to that of Lugol chromoendoscopy.38 Based on these 
results, we recommend Lugol chromoendoscopy or image-
enhanced endoscopy to determine the border of SESCC prior 
to endoscopic resection.
Statement E3
We recommend endoscopic ultrasound to define the stage 
of SESCC before endoscopic treatment (Grade of recom-
mendation: strong, Level of evidence: moderate).
Endoscopic treatments of SESCC have better prognoses when 
the depth of invasion is shallow, and unlike gastric cancer, 
SESCC invading the muscularis mucosa poses a risk of lymph 
node metastasis.39 Accurate staging of SESCC before an endo-
scopic treatment is thus important. For SESCC, endoscopic 
ultrasound accurately determines the level of infiltration by 
the primary tumor (T stage) and the presence or absence of 
lymph node metastasis (N stage). A study reported endoscop-
ic ultrasound to be 81.6% sensitive and 99.4% specific in stag-
ing esophageal cancer invading the mucosa and submucosa.40 
A meta-analysis of 19 studies reported endoscopic ultrasound 
as an excellent technique to differentiate mucosal invasion 
from submucosal invasion in SESCC (area under the summa-
ry receiver operating characteristic [ROC] curve = 0.93).26 Ad-
ditionally, in another meta-analysis that investigated whether 
endoscopic ultrasounds can differentiate between esophageal 
cancer invasions in the lamina propria, muscularis mucosa, 
and submucosa, endoscopic ultrasounds showed an excellent 
diagnostic performance (area under the summary ROC 
curve = 0.98).11
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Statement E4
We suggest magnifying endoscopy with NBI for SESCC to 
assess the depth of invasion before endoscopic treatment 
(Grade of recommendation: weak, Level of evidence: low).
A large-scale, multi-institutional prospective study that inves ti-
gated whether magnifying endoscopy with NBI can accurately 
assess the depth of invasion of esophageal cancer reported 
magnifying endoscopy with NBI to be not superior to conven-
tional endoscopy for squamous cell carcinoma (accuracy of 
magnifying endoscopy with NBI, 65.3%; accuracy of conven-
tional endoscopy, 71.4%; P = 0.375).10 A prospective study con-
ducted in Japan also reported that magnifying endoscopy with 
NBI is no better than high-resolution endoscopy and high-
frequency endoscopic ultrasound.41 However, a recent large-
scale retrospective study that investigated the performance 
of magnifying endoscopy with NBI in the assessment of the 
depth of SESCC reported a positive predictive value of 93% 
for epithelial/lamina proprial invasion, 65% for muscularis 
mucosal/superficial submucosal invasion, and 77% for deep 
submucosal invasion, demonstrating that magnifying endos-
copy with NBI is useful for determining the depth of invasion 
of SESCC before an endoscopic treatment.42 Therefore, given 
that the operator is highly experienced, it may be useful to per-
form magnifying endoscopy with NBI to determine the depth 
of invasion of SESCC before endoscopic resection.
Statement E5
We recommend ESD rather than EMR for en bloc and cura-
tive resection of SESCC confined to the mucosa (Grade of 
recommendation: strong, Level of evidence: moderate).
Endoscopic mucosal resection (EMR) is popular as it is 
relatively easy to perform and is associated with low risks of 
complications. However, studies have reported high local re-
currence rates of 2.8%–9.8% after EMR because en bloc resec-
tion is difficult by EMR, especially for large lesions.43-47 ESD is a 
technically demanding procedure with high risks of complica-
tions but is nonetheless considered appropriate for treating 
SESCC due to the high en bloc and curative resection rates and 
low risks of local recurrence. Resection techniques are usually 
chosen based on lesion size and auxiliary factors such as the 
patient’s conditions and the operator’s level of experience.
There is no randomized study comparing EMR and ESD for 
SESCC. In a meta-analysis of retrospective studies, ESD had 
higher en bloc and curative resection rates than EMR regard-
less of the lesion size. ESD had a significantly lower rate of post-
operative local recurrence than EMR (0.3% vs. 11.5%: odds ra-
tio [OR], 0.08; 95% confidence interval [CI], 0.03–0.23; P < 0.001). 
The rate of postoperative perforation was higher for ESD than 
for EMR (4.0% vs. 1.3%: OR, 2.19; 95% CI, 1.08–4.47; P = 0.03). 
However, no significant difference was noted in the rate of 
stricture formation or bleeding between the two procedures.48 
Although studies report no difference in the rate of en bloc and 
curative resection rates between cap-assisted EMR and ESD 
for lesions measuring < 10 to 15 mm,43,46,47 one meta-analysis 
reported a higher en bloc resection rate for ESD for lesions 
measuring < 10 mm (OR, 3.58; 95% CI, 1.84–7.02; P < 0.001).49
We recommend to consider ESD first regardless of the le-
sion size since ESD has higher en bloc and curative resection 
rates than EMR for SESCC confined to the mucosa and has 
complication risks within an acceptable range. In case the op-
erator lacks experience with ESD, performing EMR could be 
considered for only small lesions < 10 mm in size.
Statement E6
We recommend oral steroid or local steroid injection thera-
py for patients who develop mucosal defects in > 75% of the 
esophageal circumference after ESD to prevent esophageal 
stricture (Grade of recommendation: strong, Level of evi-
dence: moderate).
ESD can lead to scar formation around the surgical site fol-
lowed by esophageal strictures. Ono et al.50 reported that the 
risk of esophageal stricture increased in the presence of mu-
cosal defects in >75% of the esophageal circumference. Fur-
thermore, 66%–88% of patients with mucosal defects in >75% 
of the esophageal circumference that were left untreated after 
esophageal ESD developed an esophageal stricture.51-56 Pa-
tients who developed mucosal defects in 100% of the esopha-
geal circumference required an average of 33.5 endoscopic 
balloon dilation (EBD) procedures to treat esophageal stric-
ture.57
To prevent stricture after esophageal ESD, oral steroid ad-
ministration or local steroid injection therapy is used. For oral 
steroid therapy, prednisolone is administered at 30 mg per 
day starting 1 or 2 days after the procedure, and the dose is 
decremented over 2–12 weeks.54,55,57 In six studies comparing 
patients who received oral steroids following ESD to those 
who did not, oral steroid administration significantly reduced 
the rate of esophageal stricture formation by 73% (69%–80% 
without oral steroids and 18%–23% with oral steroids) (OR, 
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0.27; 95% CI, 0.13–0.58).54,55 Local steroid injection therapy 
also effectively prevents esophageal stricture. Studies reported 
a 78% reduction in the rate of esophageal stricture formation 
following local injections of triamcinolone or dexamethasone 
at the site of ESD (OR, 0.32; 95% CI, 0.13–0.83).51-53,58
In a study that compared oral steroid therapy and preven-
tive EBD, 32% of patients who underwent EBD twice per week 
for 8 weeks had an esophageal stricture, whereas only 5% of 
patients who were orally administered prednisolone at 30 mg 
per day starting 2 days after ESD and had the dose gradually 
decreased over 8 weeks had an esophageal stricture, demon-
strating that oral steroid administration is superior to preven-
tive EBD for the prevention of esophageal stricture.56
Studies on steroid administration for the prevention of 
esophageal stricture mostly involve patients who develop mu-
cosal defects in > 75% of the esophageal circumference and 
are at high risk of esophageal stricture. In a study that investi-
gated the effect of local steroid injections in patients who un-
derwent esophageal ESD regardless of the size of mucosal de-
fect, local steroid injections had a 70% preventive effect on 
esophageal strictures with the rate of stricture formation being 
11% in patients who received local steroid injections and 36% 
in those who did not receive them (OR, 0.30; 95% CI, 0.13–
0.83).58 However, considering the risk of esophageal perfora-
tion and adverse reactions associated with local steroid injec-
tions, it is advisable to consider oral steroid or local steroid in-
jection therapy only for patients who develop mucosal defects 
in > 75% of the esophageal circumference who are at high risk 
of esophageal stricture. 
Statement E7
No additional treatment is recommended after en bloc com-
plete resection of SESCC invading no more than the lamina 
propria with no lymphovascular invasion because of a very 
low risk of lymph node metastasis (Grade of recommenda-
tion: strong, Level of evidence: moderate). As the risk of 
lymph node metastasis of a tumor invading into the muscu-
laris mucosa without lymphovascular invasion is low, a 
close follow-up after en bloc complete endoscopic resection 
can be considered without additional treatment (Grade of 
recommendation: weak, Level of evidence: low). In case of a 
tumor with submucosal invasion, lymphovascular invasion, 
and/or positive vertical resection margin, additional treat-
ment is recommended (Grade of recommendation: strong, 
Level of evidence: moderate).
Since the risk of lymph node metastasis associated with SES-
CC is closely related to a tumor’s depth of invasion, it is impor-
tant to accurately evaluate the depth of invasion for deciding 
whether the endoscopic resection is curative or non-cura-
tive.59-61 Histopathological analyses of patients who underwent 
esophagectomy with dissection of the regional lymph nodes 
show that the risk of lymph node metastasis is 26.0%–53.8% in 
the presence of submucosal invasion of esophageal cancer.59-68 
Moreover, 8.3%–53.1% of the patients had lymph node metas-
tasis even when esophageal cancer invaded only the upper 
third of the submucosa. The Japan Esophageal Society and the 
ESGE guidelines define SESCC with a shallow submucosal 
invasion of ≤200 μm as a relative indication for endoscopic re-
section. However, data regarding the frequency of lymph node 
metastasis by SESCC with shallow submucosal invasion of 
≤200 μm is limited.67 The rate of lymph node metastasis is low-
er but not negligible at 0.0%–15.4% for esophageal cancer con-
fined to the mucosa.59-67 Among esophageal cancers confined 
to the mucosa, invasion of muscularis mucosa is at a higher 
risk of lymph node metastasis than invasion of lamina propria 
(8.0%–27.0% vs. 0.0%–8.7%). The risk of lymph node metasta-
sis is associated with vascular or lymphatic invasion.59,65,67,69,70 
A large-scale Japanese study reported a 5-year cumulative in-
cidence of metastasis of primary esophageal cancer invading 
the muscularis mucosa following endoscopic resection of only 
0.7%, suggesting that SESCC invading the muscularis mucosa 
can still be an indication for endoscopic resection if no lym-
phovascular invasion is observed.68 Two observational studies 
at Korean institutions supports the claim that en-doscopic re-
section can be a safe and curative treatment option in SESCC 
invading to the mucosa. In those studies, no death due to 
esophageal cancer occurred during a long-term follow-up of 
patients who underwent endoscopic resection of SESCC with 
invasion up to the mucosa.71,72 There are conflicting research 
results regarding the association between undifferentiated 
esophageal cancer and the risk of lymph node metastasis, 
indicating that undifferentiated esophageal cancer cannot be 
yet used as an absolute contraindication of endoscopic resec-
tion for SESCC. Additional data analyses are needed to derive 
more confirmative conclusions.59,61,65,68
Endoscopic resection is considered curative if histopatho-
logical evaluation shows that SESCC does not invade beyond 
the lamina propria and does not invade the vascular or lym-
phatic channels. In this case, a close follow-up may be con-
ducted without additional operations. Following en bloc resec-
tion of SESCC with muscularis mucosal invasion and no lym-
phovascular invasion, a follow-up can be considered without 
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additional operations after considering the patient’s age, ac-
companying diseases, conditions, and risk of operation since 
the risk of lymph node metastasis is low. In case of unsuccess-
ful en bloc resection, follow-up strategies considering the pos-
sibility that the histopathological assessment may have been 
inaccurate are necessary.
Additional treatments are needed in case of non-curative 
resection such as positive vertical resection margin and sub-
mucosal invasion and/or lymphovascular invasion suggesting 
the possibility of lymph node metastases. Esophagectomy 
with dissection of the regional lymph nodes is the standard 
treatment for non-curative endoscopic resection. However, 
since esophagectomy has high postoperative morbidities of 
30%–40% and mortalities of 1%–2%, physicians must consider 
the patient’s conditions before deciding whether to perform 
the surgery or not.29-31 Studies have reported relatively satisfac-
tory outcomes of chemoradiation therapy for non-curative 
endoscopic resection of SESCC, suggesting that chemoradia-




We recommend chromoendoscopy/image-enhanced en-
doscopy to determine the extent of lesion before endoscop-
ic treatment of early gastric cancer (Grade of recommenda-
tion: strong, Level of evidence: moderate).
Clearly identifying the horizontal border of the lesion before 
endoscopic resection reduces local recurrence and increases 
the likelihood of a complete resection. Chromoendoscopy has 
been used widely to accurately measure lesion borders. Re-
cent advances in endoscopy technology led to the advent of 
NBI and magnifying endoscopy now commonly used in clini-
cal settings.12,79 A study reported that chromoendoscopy using 
indigo carmine more accurately estimated lesion borders in 
early gastric cancer than white light endoscopy (75.9% vs. 
50.0%), and chromoendoscopy using indigo carmine and ace-
tic acid estimated lesion borders with 90.7% accuracy.80 A Ko-
rean study also reported that chromoendoscopy using indigo 
carmine and acetic acid estimated lesion borders in early gas-
tric cancer more accurately than white light endoscopy (84.1% 
vs. 66.9%).81 In a study that compared the accuracy of border 
prediction between magnifying endoscopy with NBI and 
chromoendoscopy using indigo carmine, the former tech-
nique estimated horizontal borders of lesions more accurately 
than the latter (81.1% vs. 72.6%).12 Magnifying endoscopy with 
NBI was also superior to white light endoscopy in terms of sen-
sitivity and specificity for assessment of lesion borders (sensi-
tivity, 92.9% vs. 42.9%; specificity, 94.7% vs. 61.0%).13 Based on 
these results, we recommend chromoendoscopy and image-
enhanced endoscopy to determine the extent of resection be-
fore endoscopic resection of early gastric cancer.
Statement G2
Endoscopic ultrasonography before endoscopic resection 
of early gastric cancer may be helpful in determining the 
depth of invasion in some patients with early gastric cancer 
(Grade of recommendation: weak, Level of evidence: mod-
erate).
Endoscopic ultrasonography is useful for assessing the depth 
of invasion in gastric cancer and determining the presence or 
absence of lymph node metastasis. In a meta-analysis on 54 
studies evaluating the efficacy of endoscopic ultrasonography 
in predicting the depth of invasion of a primary tumor in 5,601 
patients with gastric cancer, endoscopic ultrasonography ac-
curately differentiated between T3-T4 lesions and T1-T2 le-
sions with 86% sensitivity and 91% specificity.14 However en-
doscopic ultrasonography before endoscopic resection of ear-
ly gastric cancer has limited accuracy in predicting the depth 
of invasion.82-88 In a large-scale Korean prospective study, the 
accuracy of distinguishing mucosal and submucosal invasion 
in early gastric cancer was 67.4% with endoscopic ultrasonog-
raphy, which was not superior to 73.7% of conventional en-
doscopy.84 Another Korean study also reported no significant 
difference in the accuracy of depth of invasion prediction in 
early gastric cancer between endoscopic ultrasonography us-
ing a miniprobe and white light endoscopy (81.4% vs. 78.9%).83 
However, some studies report that endoscopic ultrasonogra-
phy may be useful for investigating the depth of invasion of 
early gastric cancer. According to a Japanese study, the diag-
nostic accuracy of endoscopic ultrasound was higher than 
that of white light endoscopy in predicting the depth of inva-
sion of early gastric cancer (71% vs. 63%).85 A recent study re-
ported that endoscopic ultrasonography had higher accuracy 
than chromoendoscopy in predicting the depth of invasion of 
early gastric cancer (79.1% vs. 76.5%) and that the depth of in-
vasion could be predicted with 88.3% accuracy using both 
chromoendoscopy and endoscopic ultrasonography.82 Based 
on these studies, there is still a role for endoscopic ultrasonog-
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raphy to help differentiating mucosal or submucosal infiltra-
tion of early gastric cancer. Therefore, for patients who show 
signs of submucosal invasion in a white light endoscopic ex-
amination, endoscopic ultrasonography could be used to 
more accurately examine the depth of invasion of a tumor be-
fore endoscopic resection.89
Statement G3
We recommend endoscopic resection for early gastric can-
cer of well or moderately differentiated tubular or papillary 
adenocarcinoma meeting endoscopically estimated tumor 
size ≤ 2 cm and endoscopically suspected mucosal cancer 
without ulcer (Grade of recommendation: strong, Level of 
evidence: moderate).
Endoscopic resection is a local treatment for early gastric 
cancer with a negligible risk of lymph node metastasis. Before 
Gotoda et al.90 proposed expanded indications for endoscopic 
resection in 2000, well or moderately differentiated tubular or 
papillary gastric adenocarcinoma measuring ≤2 cm in diam-
eter confined to the mucosa without ulcer and submucosal 
invasion was an indication for endoscopic resection. Thus, for 
these lesions, endoscopic resection must be considered as 
the first line of treatment. The risk of lymph node metastasis 
must be considered before performing endoscopic resection 
of early gastric cancer. Several studies have reported the risk 
of lymph node metastasis to be negligibly low in lesions that 
satisfy the aforementioned indications (0.0%–0.3%).90-92 In ad-
dition, Korean studies reported no significant difference in the 
5-year survival rate between endoscopic resection and surgi-
cal resection (93.6%–96.4% vs. 94.2%–97.2%),93-95 They also 
reported no significant difference in the 10-year survival rate 
between endoscopic resection and surgical resection (81.9% 
vs. 84.9%).93 However, endoscopic resection had a higher 
5-year cumulative incidence of metachronous gastric cancer 
than surgical resection (5.8%–10.9% vs. 0.9%–1.1%).93-95 En-
doscopic resection preserves the entire stomach, which can 
lead to metachronous tumor formation in the rest parts of the 
stomach. Therefore, even after curative endoscopic resection, 
regular follow-up endoscopy is necessary to look for meta-
chronous gastric cancer. Endoscopic resection, which pre-
serves the entire stomach, improves the quality of life, causes 
lesser complications, requires a shorter hospital stay, and is 
more cost-effective than surgical resection.93-98 In conclusion, 
we recommend endoscopic resection as the first line of treat-
ment for well or moderately differentiated tubular or papillary 
gastric adenocarcinoma measuring ≤2 cm in diameter with-
out endoscopic signs of ulcer and submucosal invasion since 
endoscopic resection is comparable to surgical resection in 
terms of survival, is associated with a satisfactory quality of 
life, and is economical.93-96
Statement G4
We suggest endoscopic resection for early gastric cancer of 
well or moderately differentiated tubular or papillary ade-
nocarcinoma with the following endoscopic findings: (1) 
mucosal cancer > 2 cm without ulcer, or (2) mucosal cancer 
≤ 3 cm with ulcer (Grade of recommendation: weak, Level 
of evidence: moderate).
The World Health Organization histological classification of 
gastric cancer published in 2000 is widely accepted as the 
standard classification system for gastric cancer, which de-
fines undifferentiated carcinoma as carcinomas without glan-
dular differentiation and squamous epithelial differentiation. 
However, most studies on endoscopic resection have classi-
fied well or moderately differentiated tubular or papillary ade-
nocarcinoma as differentiated type adenocarcinoma and 
poorly differentiated tubular adenocarcinoma and poorly co-
hesive carcinoma as undifferentiated type adenocarcinoma. 
Expansion of existing indications for endoscopic resection 
should be considered only if there is no difference in the sur-
vival rates between endoscopic resection and standard surgi-
cal treatment. In addition, surgery-related mortalities must be 
compared and reviewed to determine the permissible range 
of risk of lymph node metastasis. The risk of lymph node me-
tastasis is generally estimated based on the size of tumor, his-
tologic type and grade, depth of invasion, and presence or ab-
sence of lymphovascular invasion. The risk of lymph node 
metastasis and distant metastasis has been reported to be 
0.0%–0.21% for well or moderately differentiated tubular or 
papillary gastric mucosal adenocarcinoma measuring > 2 cm 
without ulcers or mucosal cancer measuring ≤ 3 cm with ul-
cers if the endoscopically resected tumor shows a negative re-
section margin and no lymphovascular invasion. Considering 
that the risk of lymph node or distant metastasis (0.0%–0.21%) 
is similar to the mortality of gastrectomy (0.1%–0.3%), endo-
scopic resection may be considered for the lesions described 
above.99-101 Additionally, studies reported no significant differ-
ence between the 5-year survival rate of surgical resection and 
endoscopic resection (92.0%–97.2% vs. 93.3%–96.4%), indicat-
ing that endoscopic resection is considered curative for the 
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aforementioned lesions with no requirement of further treat-
ment.95,100,102-109
Surgical resection is the standard treatment for clinically 
suspected submucosal invasive gastric cancer in preoperative 
evaluation. However, studies analyzing pathologic results of 
patients who underwent gastrectomy due to preoperatively 
suspected submucosal invasion reported that 28.8%–43.0% of 
these lesions could have been treated with endoscopic resec-
tion.110,111 Therefore, further research is needed regarding 
treatment methods for preoperatively suspected submucosal 
invasive early gastric cancer.
Statement G5
We suggest endoscopic resection for poorly differentiated 
tubular adenocarcinoma, poorly cohesive carcinoma, or 
signet ring cell carcinoma meeting the following endoscop-
ic findings: endoscopically estimated tumor size ≤ 2 cm, en-
doscopically mucosal cancer, and no ulcer in the tumor 
(Grade of recommendation: weak, Level of evidence: low).
Undifferentiated type adenocarcinoma including poorly dif-
ferentiated tubular adenocarcinoma, poorly cohesive carcino-
ma and signet ring cell carcinoma of the stomach has not 
been accepted as an indication for endoscopic resection due 
to reports that undifferentiated type adenocarcinoma is asso-
ciated with a high risk of lymph node metastasis.112,113 Howev-
er, retrospective studies reported a low incidence of extra-gastric 
metastasis during follow-up and high 5-year survival rates of 
95.0%–98.6% among patients who underwent endoscopic re-
section for undifferentiated type adenocarcinoma with muco-
sal invasion, no ulcer and ≤ 2 cm in size.100,114-118 Studies also 
reported no significant difference in long-term outcomes be-
tween endoscopic resection and surgical resection for the 
aforementioned lesions.95,100,103,118 Thus, endoscopic resection 
may be recommended for undifferentiated type gastric adeno-
carcinoma with mucosal invasion, no ulcer and ≤ 2 cm in size. 
However, since undifferentiated type adenocarcinoma tends 
to have unclear borders that contribute to low curative resec-
tion rates (45.1%–70%),115,116 it is important to clearly identify 
borders and secure a sufficient resection margin during endo-
scopic resection. In addition, even in undifferentiated type ad-
enocarcinoma, poorly differentiated tubular adenocarcinoma, 
poorly cohesive carcinoma and signet ring cell carcinoma can 
have different biological behaviors, and further studies in this 
field are needed.
Statement G6
We recommend prophylactic hemostasis of visible vessels 
on the post-resection ulcer caused by endoscopic resection 
of early gastric cancer to lower the risk of delayed bleeding 
(Grade of recommendation: strong, Level of evidence: low).
Statement G7
We recommend proton pump inhibitors to decrease the 
risk of symptoms and complications associated with iatro-
genic ulcers caused by endoscopic resection of early gastric 
cancer (Grade of recommendation: strong, Level of evi-
dence: high).
Reports on the incidence of bleeding associated with endo-
scopic resection vary depending on the definition of bleeding. 
Serious immediate bleeding that requires an intraprocedural 
blood transfusion or surgical treatment has been reported in 
< 1% of patients.119 Delayed bleeding that occurs after endo-
scopic resection is defined as bleeding from an iatrogenic ul-
cer that requires hemostasis, and its incidence has been re-
ported to be 1.3%–11.9%. Delayed bleeding usually occurs 
within 24 hours after endoscopic resection but can occur up 
to 2 weeks after endoscopic resection.120,121 Prophylactic coag-
ulation of visible vessels exposed on the base of an iatrogenic 
ulcer after endoscopic resection can effectively prevent de-
layed bleeding. One retrospective study reported a 2.47-fold 
increase in the risk of delayed bleeding when prophylactic co-
agulation was not performed.122 However, excessive prophy-
lactic coagulation can increase the risk of post-coagulation 
syndrome or delayed perforation.123,124
Postoperative administration of proton pump inhibitors or 
histamine 2 (H2) receptor blockers can prevent delayed bleed-
ing. Whether one drug is more effective than the other is un-
clear with some studies reporting proton pump inhibitors to 
be more effective in treating iatrogenic ulcers related to endo-
scopic resection,125,126 and others reporting the two drugs to be 
on a par with one another.127,128 One meta-analysis reported 
no difference between proton pump inhibitors and H2 recep-
tor blockers in their ability to treat iatrogenic ulcers and relieve 
symptoms but reported a significantly lower incidence of de-
layed bleeding in patients who were administered proton 
pump inhibitors (OR, 0.49; 95% CI, 0.25–0.95).129 Various re-
ports regarding the dose and administration period of proton 
pump inhibitors for iatrogenic ulcers and concomitant use of 
mucosal protective agents are available.130-142 Randomized tri-
als reported that administration of proton pump inhibitors be-
fore endoscopic resection is not effective in preventing de-
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layed bleeding and that second look endoscopy also did not 
effectively prevent delayed bleeding.143-145
Statement G8
We recommend endoscopic closure as the first treatment 
option for perforation that occurred during endoscopic re-
section of early gastric cancer (Grade of recommendation: 
strong, Level of evidence: low).
The incidence of perforation resulting from excessive damage 
to the muscularis propria during endoscopic resection is 
1.2%–5.2% and that of delayed perforation that occurs after 
endoscopic resection is reported at below 0.5%. The risk of in-
traoperative perforation varies depending on the location and 
size of the lesion.146 Closure by endoscopic clipping effectively 
treats intraoperative perforation, and conservative treatments 
such as fasting and antibiotic administration after successful 
endoscopic closure usually lead to symptom relief without the 
need for additional surgical treatments.147-149 However, surgical 
treatment must be considered in case of unsuccessful closure, 
signs of generalized peritonitis, or delayed perforation.150 The 
endoscopic closure must be performed by an experienced en-
doscopist. If a patient becomes hemodynamically unstable or 
has respiratory problems due to tension pneumoperitoneum, 
rapid decompression of the intra-abdominal pressure using a 
percutaneous aspiration and/or drainage of intra-abdominal 
free air is required.151 It may also be useful to switch from oxy-
gen to carbon dioxide infusion during endoscopy when perfo-
ration occurs.152
Statement G9
We recommend surgical gastrectomy if histopathological 
evaluation after endoscopic resection of early gastric cancer 
meets the criteria for non-curative resection. An exception 
applies if cancer invasion is observed at the horizontal re-
section margin only (Grade of recommendation: strong, 
Level of evidence: moderate).
Statement G10
We recommend additional endoscopic management rather 
than surgical gastrectomy if histopathological evaluation of 
endoscopically resected early gastric cancer specimen 
shows positive involvement at the horizontal resection mar-
gin without any other findings compatible with non-cura-
tive resection (Grade of recommendation: strong, Level of 
evidence: moderate).
Curative resection of an absolute indication lesion is assumed 
when well or moderately differentiated tubular or papillary 
adenocarcinoma confined to the mucosa measuring < 2 cm 
with no histopathological evidence of lymphovascular inva-
sion and ulcers and a negative resection margin is observed 
following endoscopic en bloc resection of a lesion. Curative re-
section of an expanded indication lesion is considered when 
any of the following conditions are observed after en bloc re-
section: (1) differentiated type mucosal adenocarcinoma such 
as well or moderately differentiated tubular or papillary ade-
nocarcinoma with a negative resection margin and ulcers of 
≥ 2 cm and without lymphovascular invasion; (2) mucosal ad-
enocarcinoma of ≤ 3 cm accompanied by ulcers; (3) submu-
cosal invasive cancer of ≤ 3 cm with submucosal invasion 
depth ≤ 500 µm; or (4) undifferentiated type adenocarcinoma 
such as poorly differentiated tubular adenocarcinoma, poorly 
cohesive carcinoma, and signet ring cell carcinoma measur-
ing ≤ 2 cm confined to the mucosa. Lesions that do not meet 
these criteria for curative resection are considered to have un-
dergone non-curative resection.1,120,153 The risk of lymph node 
metastasis is reported to be 2.6%–3.0% for differentiated type 
adenocarcinoma that satisfy the criteria for non-curative re-
section, with the exception of differentiated type adenocarci-
noma with a positive horizontal resection margin, and 5%–
20% for undifferentiated type adenocarcinoma.90,154,155 In a 
large-scale cohort study on patients who received additional 
surgical treatments due to non-curative resection, lymphatic 
invasion was associated with the highest risk of lymph node 
metastasis. Large tumor size, positive vertical resection mar-
gin, vascular invasion, and submucosal invasion depth > 500 
µm are reported to increase the risk of lymph node metastasis 
to a similar extent.156 Many studies have demonstrated that 
lymphovascular invasion is an important risk factor of lymph 
node metastasis.157-159 Considering the risk of lymph node me-
tastasis, patients may require additional surgical gastrectomy 
including regional lymphadenectomy when they satisfy the 
criteria for non-curative resection, with the exception of hav-
ing a positive horizontal resection margin only. Differentiated 
type mucosal adenocarcinomas less than 2 cm in size that 
show lymphovascular invasion are reported to have low risk 
of lymph node metastasis, in which case the need for addi-
tional surgical procedures is not clear.160 Although some stud-
ies comparing surgical resection following non-curative resec-
tion vs. no surgery reported no additional benefits of addition-
al surgery,161-163 most retrospective studies have reported an 
increase in overall survival and disease-specific survival in pa-
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tients who underwent surgical resection.158,159,164-167 Further-
more, additional surgical resection following non-curative en-
doscopic resection has also been reported to increase survival 
among patients of advanced age.168-170
Differentiated type adenocarcinoma with a positive hori-
zontal resection margin that meet all the other criteria for cu-
rative resection following en bloc resection is associated with a 
low risk of lymph node metastasis. A cohort study that fol-
lowed up patients who had this type of cancer and did not re-
ceive additional treatments reported low 5-year recurrence 
rates among these patients and that recurrent tumors could 
be curatively treated without any mortality associated with 
gastric cancer.171 Therefore, additional endoscopic resection 
or argon plasma coagulation treatment may be used instead 
of surgical resection for tumors with a positive horizontal re-
section margin. Retrospective cohort studies reported favor-
able prognoses following these endoscopic treatments and 
suggested that additional endoscopic treatments within 3 
months after the initial endoscopic resection are associated 
with low recurrence rates.172-174 However, it is impossible to de-
termine whether resection is curative following argon plasma 
coagulation since histological evaluation is impossible; thus, a 
close follow-up is required after argon plasma coagulation.
Statement G11
We recommend Helicobacter pylori eradication treatment 
after endoscopic resection of early gastric cancer in H. pylo-
ri-infected patients (Grade of recommendation: strong, Lev-
el of evidence: high).
H. pylori eradication may be considered for patients who test 
positive for H. pylori following an endoscopic treatment of 
early gastric cancer to reduce the risk of metachronous recur-
rence. Fukase et al.175 reported that H. pylori eradication sig-
nificantly reduced the risk of metachronous gastric cancer in 
patients with early gastric cancer after endoscopic resection in 
their multicenter randomized controlled study in 2008 (haz-
ard ratio [HR], 0.339; 95% CI, 0.157–0.729). Based on this 
study, most clinical practice guidelines recommend H. pylori 
eradication after endoscopic resection of early gastric can-
cer.176-180 Four meta-analyses investigating whether H. pylori 
eradication after endoscopic resection of early gastric cancer 
prevents metachronous gastric cancer reported that H. pylori 
eradication significantly reduces the risk of metachronous 
gastric cancer to 0.42–0.51.181-184 A Korean prospective ran-
domized double-blind, placebo-controlled trial published in 
2018 also showed that 50% and 68% of metachronous gastric 
cancer was reduced in patients who received eradication 
therapy and for those in whom eradication was successful af-
ter endoscopic treatment of early gastric cancer, respective-
ly.185 Another Korean prospective randomized study pub-
lished in 2018 reported a 2.02-fold increase in the risk of meta-
chronous gastric cancer in the control group compared with 
the eradication group.186 Therefore, we recommend H. pylori 
eradication following endoscopic resection of early gastric 
cancer for prevention of metachronous gastric cancer.
Statement G12
We recommend regular surveillance endoscopy every 6–12 
months for patients who have had curative endoscopic re-
section of early gastric cancer based on absolute or expand-
ed criteria for early detection of metachronous gastric cancer 
(Grade of recommendation: strong, Level of evidence: low).
Surveillance strategy for the patients after endoscopic resec-
tion has similar follow-up plans compared with those after 
surgical gastrectomy. However, more careful follow-up should 
be performed after endoscopic resection of early gastric can-
cer as it is associated with high incidence of synchronous mul-
tiple gastric cancers and metachronous gastric cancers. The 
Korean clinical practical guideline for gastric cancer recom-
mends patients who undergo endoscopic treatment for early 
gastric cancer to have a follow-up endoscopic examination on 
a yearly basis.187 The Japanese guideline for endoscopic resec-
tion for early gastric cancer recommend an endoscopy exami-
nation at a 6- to12-month interval following curative endo-
scopic resection to detect metachronous gastric cancer and 
additionally for those with expanded curative criteria recom-
mend ultrasonography or CT—also at 6- to 12-month inter-
val—to detect possible metastasis.7,120 The ESGE guidelines for 
ESD recommend undergoing the first endoscopic surveil-
lance at 3–6 months after curative endoscopic resection, and 
regular endoscopic examinations on a yearly basis thereafter.1 
They recommend considering staging abdominal CT scan for 
expanded indication lesions.1
The purpose of follow-up examinations after endoscopic re-
section is to detect local recurrence at the resection site, syn-
chronous or metachronous gastric cancer, and extra-gastric 
metastases. One meta-analysis reported the incidence of local 
recurrence following endoscopic treatment to be 0.3% for ESD 
and 5.2% for EMR.49 A Korean multicenter prospective study 
published in 2018 reported the incidence of local recurrence 
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to be 0.7% in patients who had curative ESD and 2.4% who 
had non-curative ESD.188 Thus, since the incidence of local re-
currence following curative ESD is below 1%, detecting syn-
chronous or metachronous gastric cancer must be prioritized 
before detecting local recurrences. Since patients with early 
gastric cancer who receive endoscopic resection have most of 
their gastric mucosa intact, they are more prone to developing 
metachronous and synchronous gastric cancers compared 
with those after surgical gastrectomy. If synchronous cancer is 
defined as cancer detected within 1 year after an endoscopic 
resection, and metachronous cancer as cancer detected start-
ing 1 year after an endoscopic resection, the incidence of the 
respective cancers is reported to be 0.87%–11.0% and 3.6%–
22.7%.101,189-191 A Japanese study published in 2015 reported 
the incidence of metachronous recurrence to increase to 9.5%, 
13.1%, and 22.7% at 5, 7, and 10 years, respectively, after cura-
tive ESD.191 Another Japanese multicenter study reported the 
annual average incidence of metachronous gastric cancer to 
be 3.5%.189 A recently conducted Korean study reported that 
the annual average incidence of synchronous and metachro-
nous gastric cancer is 2.47%, and that patients who had follow-
up examinations for over 1 year were significantly more likely 
to require surgery for metachronous cancer than patients who 
underwent follow-up examinations for ≤ 1 year.192 Based on 
these results, early detection of metachronous and synchro-
nous gastric cancer that develops after endoscopic resection 
is crucial for a successful follow-up. Patients must undergo fol-
low-up endoscopy every 6–12 months within 5 years after an 
endoscopic resection for the detection of local recurrence and 
metachronous or synchronous cancer. It is advisable to con-
tinue undergoing follow-up endoscopy after the 5-year mark 
as the risk of metachronous gastric cancer consistently in-
creases even after 5 years.191,193 Further research is needed to 
establish more detailed and precise standards regarding the 
interval and duration of follow-up surveillance endoscopy.
Statement G13
We suggest regular abdominopelvic CT scan of 6- to 
12-month interval for detection of extra-gastric recurrence 
after curative endoscopic resection of early gastric cancer 
based on absolute and expanded criteria (Grade of recom-
mendation: weak, Level of evidence: low).
Very few clinical practice guidelines on follow-up abdomino-
pelvic CT scan for endoscopic resection of early gastric cancer 
are available. Japanese guidelines recommend routine ultra-
sounds or CT at a 6- to 12-month interval for lesions meeting 
expanded criteria,7,120 and ESGE guideline recommends to 
consider staging abdominopelvic CT for lesions meeting ex-
panded criteria.1 A Korean study published in 2015 reported 
lymph node metastases 5 and 4 years after curative resection 
in two patients with absolute and expanded criteria lesions, 
respectively.101 In another Korean study on 15 cases of extra-
gastric recurrence published in 2017, 66.7% (4/6) of expanded 
criteria lesions and 83.3% (5/6) of out-of-indication lesions 
showed extra-gastric recurrences on CT without any intragas-
tric recurrences, demonstrating the need for follow-up CT in 
patients with expanded criteria lesions.194
However, another Korean study reported detecting extra-
gastric lymph node recurrence on CT in only two (one case of 
absolute criteria and one of expanded criteria) among total of 
2,182 patients who underwent curative endoscopic resection, 
suggesting that CT after curative endoscopic resection is un-
necessary for patients who meet expanded criteria consider-
ing the cost and radiation dose of CT.195 In addition, a study 
that followed up 894 mucosal cancers using endoscopy and 
abdominopelvic CT following their curative endoscopic resec-
tion reported CT signs of recurrence in only two cases, sug-
gesting that CT plays a minimal role in follow-up after endo-
scopic resection.196 Precise standards for the target subjects 
and interval of follow-up abdominopelvic CT are yet to be es-
tablished, and further research is needed in this regard.
EARLY COLORECTAL CANCER
Statement C1
Poor histologic types (poorly differentiated adenocarcino-
ma, signet ring cell carcinoma, and mucinous carcinoma), 
deep submucosal invasion, lymphovascular invasion, and 
intermediate-to-high-grade tumor budding at the site of 
deepest invasion are risk factors of lymph node metastasis 
in early colorectal cancer (Grade of recommendation: 
strong, Level of evidence: moderate).
Predicting the risk of potential lymph node metastasis of early 
colorectal cancer affects the decision of whether to addition-
ally perform a radical surgery following endoscopic or surgical 
local excision of early colorectal cancer. Histologic grades are 
a traditional predictor of lymph node metastasis of early 
colorectal cancer. Poor histologic types (poorly differentiated 
adenocarcinoma, signet ring cell carcinoma, and mucinous 
carcinoma) are associated with a higher risk of lymph node 
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metastasis than moderately-to-well differentiated adenocarci-
noma, and the risk of metastasis increases in proportion to the 
histologic grade.197-202 Multivariate analyses have shown that 
poor histologic types (poorly differentiated adenocarcinoma, 
signet ring cell carcinoma, mucinous carcinoma) have in-
creased ORs (2.93–45.9) for lymph node metastasis com-
pared with well differentiated adenocarcinomas.203-205 Four 
meta-analyses also showed early colorectal cancers with poor 
histologic types to have an increased risk of lymph node me-
tastasis with ORs ranging between 4.78 and 8.27.8,206-208
Well differentiated intramucosal colorectal cancer does not 
metastasize to the lymph nodes, whereas 6%–20% of early 
colorectal cancers that invade the submucosa metastasize to 
the lymph nodes.8,206-209 In studies using the relative depth of 
submucosal invasion, pedunculated polyps are classified ac-
cording to the Haggitt classification, and nonpedunculated 
polyps are classified using the Kudo or Kikuchi classification 
based on the depth of invasion.210-212 The risk of lymph node 
metastasis increases in proportion to the depth of submucosal 
invasion determined by these classification methods (Haggitt 
level 4 and Kudo sm2-3).197-199,205,209,213,214 In studies that mea-
sured the absolute depth of submucosal invasion from the 
muscularis mucosa and evaluated the risk of lymph node me-
tastasis, depth of vertical invasion of ≥ 1,000 μm of nonpedun-
culated cancer were associated with the risk of lymph node 
metastasis, and the risk increased in proportion to the depth 
of invasion.201,203,215-219 In meta-analyses evaluating the risk of 
lymph node metastases in colorectal cancer, depth of submu-
cosal invasion of ≥ 1,000 μm increased the OR of lymph node 
metastasis to 3.0–5.93.8,206-208 However, the risk of metastasis 
based on the absolute depth of submucosal invasion has a rel-
atively low predictive power.8,201 For this reason, the width of 
invasion has been also used as a quantitative measure of the 
risk of lymph node metastasis to complement the absolute 
depth of invasion.
In many studies including multivariate analyses, lympho-
vascular invasion was an independent risk factor for predict-
ing local lymph node metastasis.198-205,220 There have been five 
meta-analyses that evaluated the risks for lymph node metas-
tasis according to lymphatic and vascular invasion; lymphatic 
invasion (OR, 4.15–6.91), vascular invasion (OR, 2.20–4.03), 
and lymphovascular (either lymphatic or vascular) invasion 
(OR, 3.9–5.47) all had increased lymph node metasta-
ses.8,206-208,221
Tumor budding is defined as the presence of a single tumor 
cell or a cluster of < 5 tumor cells at the tumor-invasive front of 
resected specimens.222,223 The definition of tumor budding var-
ies between studies, but tumor budding is generally classified 
as intermediate-to-high if ≥ 5 tumor buds are observed. Inter-
mediate-to-high grade tumor budding is associated with an 
increased risk of lymph node metastasis.198,201,219,224,225 Accord-
ing to some meta-analyses, the presence of tumor budding in-
creases the OR of lymph node metastasis by 3.26- to 7.74-
fold.8,206-208,221,223 A recent large-scale, multi-institutional Japa-
nese study suggests that poorly differentiated clusters at the 
invasive front are also a useful histologic predictor of lymph 
node metastasis.201,225 Poorly differentiated clusters are com-
posed of ≥ 5 cancer cells present at invasive front of the tumor 
that lack full glandular formation. Therefore, compared with 
tumor budding, poorly differentiated clusters are more easily 
recognized in hematoxylin and eosin staining and do not re-
quire auxiliary immunohistochemical staining.
Statement C2
Endoscopic resection of submucosal colorectal cancer with 
a high risk of lymph node metastasis has a higher recur-
rence rate than surgical resection. Therefore, we recom-
mend additional surgery if histological signs after endoscop-
ic resection suggest a high risk of lymph node metastasis 
(Grade of recommendation: strong, Level of evidence: high).
Early colorectal cancer confined to the mucosa of the large in-
testine does not metastasize to the lymph nodes. Thus, com-
plete endoscopic resection of a primary tumor eliminates the 
possibility of recurrence, and no further treatment is required 
in case of mucosal colorectal cancer. A population-based 
study conducted in the Uinted States reported no difference 
in the 5-year survival rate between endoscopic resection and 
surgical treatment for mucosal or submucosal colorectal can-
cers ( ≤ stage 1) with a longest diameter of ≤ 4 cm.226 Mounzer 
et al.227 also reported no difference in 5-year colorectal cancer-
specific recurrence-free survival rates (97.6% vs. 97.5%; P =  
0.75) and colorectal cancer-specific mortalities (HR, 1.10; 95% 
CI, 0.72–1.69; P = 0.65) between endoscopic resection and sur-
gical treatment for colorectal cancer confined to the mucosa. 
However, one study has reported significantly lower recur-
rence-free survival rates and higher colorectal cancer-specific 
mortalities for endoscopic resection of submucosal colorectal 
cancer than for surgical treatment (HR, 2.40; 95% CI, 1.75–
3.29; P < 0.001).227 In addition, studies comparing endoscopic 
resection and surgical resection for submucosal colorectal 
cancer reported local recurrence rates of 2.3%–6.4% for endo-
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scopic resection228-230 and relatively low local recurrence rates 
of 0.9%–1.87% for surgical resection.228-230 Prognoses after en-
doscopic and surgical resection depend on whether the sub-
mucosal colorectal cancer is associated with a high risk of 
lymph node metastasis. A Korean study conducted in 2014 re-
ported no difference between endoscopic resection and surgi-
cal resection in the mean 37 months (range, 6–98 months) cu-
mulative incidence of recurrence in case of mucosal and su-
perficial submucosal colorectal cancer with low risks of lymph 
node metastasis (P = 0.641).231 Yoda et al.232 reported a high 
5-year recurrence-free survival rate of 98% for low-risk submu-
cosal colorectal cancer. Conversely, early colorectal cancer ac-
companied by risk factors of lymph node metastasis was asso-
ciated with a significantly higher incidence of lymph node me-
tastasis (15.5%) as opposed to when early colorectal cancer 
was not accompanied by the risk factors (7.1%) (P = 0.001).229 
In another Japanese study,232 higher 5-year recurrence-free 
survival rates were observed in patients with high-risk, early 
submucosal colorectal cancer who underwent additional sur-
gery after endoscopic treatment than in those who did not un-
dergo additional surgery (97% vs. 89%; P = 0.130). Succeeding 
studies have reported high recurrence rates and significantly 
lower survival rates for early colorectal cancer accompanied 
by risk factors of lymph node metastasis that was treated en-
doscopically only.233-235 Thus, although endoscopic resection 
effectively treats mucosal colorectal cancer and submucosal 
colorectal cancer without the risk factors of lymph node me-
tastasis, additional surgery should be considered for submu-
cosal colorectal cancer with the risk factors of lymph node 
metastasis.
Statement C3
We recommend endoscopic assessment of pit patterns and 
vascular patterns to estimate the depth of submucosal inva-
sion before endoscopic resection of early colorectal cancer 
(Grade of recommendation: strong, Level of evidence: high).
Submucosal colorectal cancer accompanied by risk factors of 
lymph node metastasis requires surgery. Many studies have 
investigated the association between the depth of submucosal 
invasion, which is a risk factor for lymph node metastasis, and 
endoscopic features. Estimating the depth of invasion prior to 
treatment of early colorectal cancer is essential for choosing 
the appropriate method of surgical or endoscopic treatment, 
and this can be done using magnifying chromoendoscopy 
and NBI.
Kudo’s pit pattern classification is useful for estimating the 
depth of submucosal invasion in early colorectal cancer (Ta-
ble 5). Type V, especially VN pit pattern observed by magnify-
ing chromoendoscopy indicates a high possibility of deep 
submucosal invasion.236-238 Studies analyzing the pit patterns 
of lesions suspected as early colorectal cancer reported the in-
cidence of submucosal invasion to be mere 1%, 5%, and 8% for 
type IIIL, IIIS, and IV pit patterns, respectively, but 14% for type 
VI and 80% for type VN.
239 The sensitivity of pit patterns in esti-
mating the depth of submucosal invasion varies depending 
on the macroscopic appearance of the lesions. The diagnostic 
accuracy of pit pattern for deep submucosal invasion in pol-
ypoid, flat, and depressed lesions was 75.8%, 85.7%, and 98.6%, 
respectively, and are thus useful for diagnosing deep submu-
cosal colorectal cancer and selecting an appropriate treat-
ment method.240 A meta-analysis on 17 studies that analyzed 
the diagnostic performance of magnifying chromoendoscopy 
reported magnifying chromoendoscopy to have 81% sensitivi-
ty and 95% specificity in diagnosing deep submucosal inva-
sion.15 A meta-analysis on nine studies including three ab-
stracts in which magnifying chromoendoscopy had 84% sen-
sitivity and 97% specificity confirmed the diagnostic useful-
ness of magnifying chromoendoscopy.241 Indigo carmine and 
crystal violet are commonly used in magnifying chromoen-
doscopy with no significant difference in diagnostic accuracy 
between the two.15
NBI is used to examine the microvascular architecture and 
Table 5. Kudo’s Pit Pattern for the Endoscopic Diagnosis of Colorectal Neoplasia238
Pit pattern 




Asteroid pits Tubular or round 
pits, smaller than 
the normal pits
Tubular or round 






sizes of type IIIS, 




















Chan Hyuk Park, et al. • Endoscopic resection of early gastrointestinal cancer
144 www.irjournal.org
Silvio Danese, et al. • iSTART consensus recommendations
surface structure. NBI findings suggesting deep submucosal 
invasion are as follows: completely unclear or amorphous sur-
face pattern, severely irregular thickness and arrangement of 
capillary vessels, and avascular or loose microvessel ar-
eas.242-244 Several NBI classification systems have been pro-
posed to aid optical diagnosis of colorectal tumors, such as Sa-
no’s classification, Hiroshima’s classification, and later, NBI In-
ternational Colorectal Endoscopic (NICE) classification, and 
the Japan NBI Expert Team (JNET) classification (Table 6). 
The sensitivity, specificity, and accuracy of Sano IIIA/IIIB for 
differentiating intramucosal/superficial submucosal cancer 
from deep submucosal cancer are 85%, 89%, and 88%, respec-
tively.245 The diagnostic sensitivity, specificity, and accuracy of 
Hiroshima class C3 patterns for deep submucosal cancer are 
67%, 99%, and 93% with excellent interobserver and intraob-
server agreement (κ = 0.749 and κ = 0.745, respectively).246 
JNET type III had diagnostic sensitivity, specificity, and accu-
racy of 55.4%, 99.8%, 96.6%, respectively.247,248 In a meta-analy-
sis on 13 studies on the accuracy of NBI in diagnosing deep 
submucosal cancer, NBI had 77% sensitivity and 98% specific-
ity.15 A recent meta-analysis on 17 studies including three ab-
stracts reported NBI to have 74% sensitivity and 98% specifici-
ty,241 demonstrating that NBI accurately estimates the deep 
submucosal invasion in early colorectal cancer.
In addition to pit patterns and surface microvascular chang-
es, the hardness of a lesion, deep and irregular depression on 
the tumor surface, absence of changes in the tumor shape 
upon air inflation, fold convergence toward the tumor, and 
non-lifting signs (the submucosa below the lesion does not lift 
when a solution is injected into the submucosa) are macro-
scopic signs of deep submucosal cancer.249,250 The non-lifting 
sign is reported to indicate submucosal fibrosis or deep sub-
mucosal invasion,251 but it has lower sensitivity and accuracy 
in predicting deep submucosal cancer than other macroscopic 
endoscopic findings associated with deep submucosal inva-
sion.252 Thus, to date, there is insufficient evidence to prove that 
non-lifting sign is a highly useful predictor of deep submucosal 
invasion. In a meta-analysis on six studies assessing the accu-
racy of macroscopic appearance in predicting deep submuco-
sal cancer, macroscopic appearance had 80%–98% specificity 
but only 18%–66% sensitivity.15 Therefore, magnifying chromo-
endoscopy and NBI may be more useful for predicting deep 
submucosal cancer than macroscopic appearance.15
A meta-analysis comparing the accuracy of magnifying 
chromoendoscopy and NBI in predicting deep submucosal 
cancer reported no difference in sensitivity (magnifying chro-
moendoscopy 81% vs. NBI 77%, P = 0.41) and specificity (95% 
vs. 98%, P = 0.09) between the two techniques. In a recent me-
ta-analysis on 17 studies including three abstracts, there was 
no difference in specificity between magnifying chromoen-
doscopy and NBI, but magnifying chromoendoscopy had a 
higher sensitivity (84% vs. 74%, P < 0.01).253 A questionnaire 
survey conducted among 30 experts on magnifying and im-
age-enhanced endoscopy showed that magnifying chromo-
endoscopy is superior to NBI in predicting deep submucosal 
cancer (88% vs. 83%, P = 0.0013).253 However, since most of the 
studies included in these meta-analyses were conducted in 
Korea and Japan, further research is needed.
In conclusion, for macroscopic signs of deep submucosal 
invasion, Kudo VN pit patterns, Sano IIIB, Hiroshima C3, and 
JNET type 3, the risk of deep submucosal invasion is high and 
primary surgery should be performed. Whereas the pit pat-
terns and the NBI findings have excellent specificity, the sensi-
tivity is relatively low in diagnosing deep submucosal inva-
sion. They may have excellent diagnostic accuracy, but are not 
substitutes for histopathological features. Thus, if a lesion with 
Table 6. JNET Classification for the Endoscopic Diagnosis of Colorectal Neoplasia246
JNET classification JNET 1 JNET 2A JNET 2B JNET 3
Vessel pattern Invisible Regular caliber





Interruption of thick vessels
Surface pattern Regular dark or white spots




Irregular or obscure Amorphous area








Deep submucosal invasive 
cancer
JNET, Japan narrow band imaging (NBI) Expert Team.
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high risk features for deep submucosal invasion can be safely 
and easily resected by endoscopy, endoscopic resection can 
be tried first and the need for further surgery may be deter-
mined based on histopathologic findings of endoscopic resec-
tion specimen. 
Statement C4
En bloc and histologically complete resection should be 
achieved for endoscopic treatment of a suspected or estab-
lished early colorectal cancer. We recommend ESD for the 
treatment of endoscopically resectable early colorectal can-
cer which cannot be resected en bloc using EMR technique 
(Grade of recommendation: strong, Level of evidence: mod-
erate).
Deep submucosal invasion, poor histologic types (poorly dif-
ferentiated adenocarcinoma, signet ring cell carcinoma, and 
mucinous carcinoma), lymphovascular invasion, tumor bud-
ding/poorly differentiated clusters are risk factors of lymph 
node metastasis from early colorectal cancer. Additional sur-
gery is required when any of these histopathological signs or 
histologically incompletely resected submucosal cancer such 
as positive vertical resection margin is observed following en-
doscopic resection. En bloc resection is important for assess-
ing the need for additional surgery as it increases the rate of 
curative resection of early colorectal cancer and allows accu-
rate histopathologic evaluation.49,254-260 In a meta-analysis on 
studies comparing between ESD and EMR of colorectal le-
sions conducted by Fujiya et al. in 2015, the rate of en bloc re-
section was 91.7% for ESD and 46.7% for EMR with an OR of 
6.84 (95% CI, 3.30–14.18); ESD had a higher en bloc resection 
rate than EMR. In the same study, the rate of curative resec-
tion was also significantly higher for ESD (80.3%) than for 
EMR (42.3%) with an OR of 4.26 (95% CI, 3.77–6.57).257 In a 
meta-analysis on studies comparing ESD and EMR for sessile 
colorectal lesions measuring ≥ 20 mm conducted by Arezzo 
et al. in 2016, the rate of en bloc resection was 89.9% for ESD 
and 34.9% for EMR with a relative risk of 1.93 (95% CI, 1.46–
2.54).258 Additionally, the rate of R0 resection was 79.6% for 
ESD and 36.2% for EMR with a relative risk of 2.01 (95% CI, 
1.76–2.29). Based on these results, Arezzo et al.258 concluded 
that ESD is superior to EMR for en bloc resection and R0 re-
section of sessile colorectal lesions measuring ≥ 20 mm.
Reports on the complications of colon polypectomy includ-
ing bleeding and perforation have varied between stud-
ies.257-259 One meta-analysis reported the incidence of perfora-
tion to be higher for ESD (4.0%–5.7%) than for EMR (0.8%–
1.4%).259 Most complications occurring after ESD can be treat-
ed endoscopically, and < 1% of all colorectal lesions require 
surgery due to complications of ESD; therefore, ESD is accept-
ably safe considering the high efficacy of the procedure.261 
However, the risk of complications and the rate of en bloc or 
curative resection significantly depend on the operator’s level 
of experience since ESD of colorectal lesions is more difficult 
to perform than other polypectomy methods of colorectal le-
sions.262,263 Therefore, physicians experienced in therapeutic 
endoscopy after sufficient training of ESD must perform 
colorectal ESD in clinical settings where they can cope with 
emergency situations due to ESD-related complications.262-266
CONCLUSION
Endoscopic resection of early gastrointestinal cancer causes 
fewer adverse events, requires a shorter hospital stay, does not 
require bowel resection, and is more economical than surgi-
cal resection. However, endoscopic resection is not indicated 
for all patients with early gastrointestinal cancer. It is impor-
tant to select patients with early gastrointestinal cancer that 
can be treated by endoscopic resection. Furthermore, excel-
lent long-term outcomes can be ensured only via appropriate 
post-resection care such as additional surgery if necessary 
and regular follow-up after endoscopic resection. This clinical 
practice guideline proposes a standard treatment process for 
gastroenterologists performing endoscopic resection, thereby 
contributing to the prevention of unnecessary health care or 
inappropriate treatments and to the provision of relevant clini-
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Supplementary Material 1. PICOs for Each Statement 
1. Description of PICOs for Superficial Esophageal Squamous Cell Carcinoma
Statement E1: We recommend endoscopic resection for SESCC without distant or lymph node metastasis, excluding those with 
obvious submucosal invasion. (Grade of recommendation: strong, Level of evidence: moderate)
Q1. What are the indications for endoscopic resection of superficial esophageal squamous cell carcinoma?
P atient:  Patients who undergo either endoscopic resection or esophagectomy for superficial esophageal squamous cell carcinoma 




Study design: Randomized controlled trial (RCT) or non-RCT
Statement E2: We recommend Lugol chromoendoscopy and/or image-enhanced endoscopy to define the extent of lesion before 
endoscopic treatment of SESCC. (Grade of recommendation: strong, Level of evidence: moderate) 
Q1.  Does chromoendoscopy or image-enhanced endoscopy before endoscopic resection of superficial esophageal squamous cell 
carcinoma help the evaluation of the lateral margin of the lesion?
Patient: Patients who were diagnosed with superficial esophageal squamous cell carcinoma
Intervention: Chromoendoscopy, image-enhanced endoscopy
Comparator: No chromoendoscopy or image-enhanced endoscopy after diagnosis of superficial esophageal squamous cell carcinoma
Outcome: Lateral margin
Study design: RCT or non-RCT
Statement E3: We recommend endoscopic ultrasound to define the stage of SESCC before endoscopic treatment. (Grade of rec-
ommendation: strong, Level of evidence: moderate)
Q1.  Does endoscopic ultrasound (EUS) before endoscopic resection of superficial esophageal squamous cell carcinoma help to 
stage the disease?
Patient: Patients who were diagnosed with superficial esophageal squamous cell carcinoma 
Intervention: EUS
Comparator: No EUS after diagnosis of superficial esophageal squamous cell carcinoma
Outcome: Depth of invasion, lymph node metastasis
Study design: RCT or non-RCT
Statement E4: We suggest magnifying endoscopy with narrow band imaging for SESCC to assess the depth of invasion before 
endoscopic treatment. (Grade of recommendation: weak, Level of evidence: low)
Q1.  Does magnifying endoscopy with narrow band imaging (MENBI) before endoscopic resection of superficial esophageal squa-
mous cell carcinoma help the evaluation of the depth of invasion?
See “Clinical practice guideline for endoscopic resection of early gastrointestinal cancer” on page 127-157.
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Patient: Patients who were diagnosed with superficial esophageal squamous cell carcinoma
Intervention: MENBI
Comparator: No MENBI after diagnosis of superficial esophageal squamous cell carcinoma
Outcome: Depth of invasion
Study design: RCT or non-RCT
Statement E5: We recommend endoscopic submucosal dissection rather than endoscopic mucosal resection for en bloc and cu-
rative resection of SESCC confined to the mucosa. (Grade of recommendation: strong, Level of evidence: moderate)
Q1.  Is ESD more effective than EMR in patients with superficial esophageal squamous cell carcinoma in terms of en bloc resec-
tion, R0 resection and curative resection?
Patient: Patients who undergo endoscopic resection for superficial esophageal squamous cell carcinoma
Intervention: Endoscopic submucosal dissection 
Comparator: Endoscopic mucosal resection 
Outcome: en bloc resection, R0 resection, curative resection
Study design: RCT or non-RCT
Statement E6: We recommend oral steroid or local steroid injection therapy for patients who develop mucosal defects in >75% of 
the esophageal circumference after endoscopic submucosal dissection to prevent esophageal stricture. (Grade of recommenda-
tion: strong, Level of evidence: moderate)
Q1.  Is steroid administration needed after endoscopic resection in patients with superficial esophageal squamous cell carcinoma 
to decrease the risk of stenosis?
Patient: Patients who undergo endoscopic resection for superficial esophageal squamous cell carcinoma
Intervention: Steroid administration after endoscopic resection (oral administration or local injection)
Comparator: No steroid administration after endoscopic resection
Outcome: Stenosis rate, number of endoscopic dilatation, adverse event
Study design: RCT or non-RCT
Statement E7: No additional treatment is recommended after en bloc complete resection of SESCC invading no more than the 
lamina propria with no lymphovascular invasion because of a very low risk of lymph node metastasis. (Grade of recommenda-
tion: strong, Level of evidence: moderate) As the risk of lymph node metastasis of a tumor invading into the muscularis mucosa 
without lymphovascular invasion is low, a close follow-up after en bloc complete endoscopic resection can be considered 
without additional treatment. (Grade of recommendation: weak, Level of evidence: low) In case of a tumor with submucosal 
invasion, lymphovascular invasion, and/or positive vertical resection margin, additional treatment is recommended. (Grade of 
recommendation: strong, Level of evidence: moderate)
Q1.  Is there a difference between observation without surgery and rescue surgery in terms of recurrence and survival in patients who 
achieve R0 resection by endoscopic resection for mucosal esophageal squamous cell carcinoma without lymphovascular inva-
sion?
P atient:  Patients who achieve R0 resection by endoscopic resection for mucosal esophageal squamous cell carcinoma without lym-
phovascular invasion
Intervention: Observation
Comparator: Rescue (additional) surgery
Outcome: Recurrence and survival rates
Study design: RCT or non-RCT
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2. Description of PICOs for Early Gastric Cancer
Statement G1: We recommend chromoendoscopy/image-enhanced endoscopy to determine the extent of lesion before endo-
scopic treatment of early gastric cancer (Grade of recommendation: strong, Level of evidence: moderate)
Q1.  Does chromoendoscopy or image-enhanced endoscopy before endoscopic resection of early gastric cancer help the evalua-
tion of the lateral margin of the lesion?
Patient: Patients who were diagnosed with early gastric cancer
Intervention: Chromoendoscopy, image-enhanced endoscopy
Comparator: No chromoendoscopy or image-enhanced endoscopy after diagnosis of early gastric cancer
Outcome: Lateral margin
Study design: RCT or non-RCT
Statement G2: Endoscopic ultrasonography before endoscopic resection of early gastric cancer may be helpful in determining 
the depth of invasion in some patients with early gastric cancer. (Grade of recommendation: weak, Level of evidence: moderate)
Q1. Does EUS before endoscopic resection of early gastric cancer help the evaluation of the depth of invasion?
Patient: Patients who were diagnosed with early gastric cancer
Intervention: EUS
Comparator: No EUS after diagnosis of early gastric cancer
Outcome: Depth of invasion
Study design: RCT or non-RCT
Statement G3: We recommend endoscopic resection for early gastric cancer of well or moderately differentiated tubular or 
papillary adenocarcinoma meeting endoscopically estimated tumor size ≤ 2 cm and endoscopically suspected mucosal cancer 
without ulcer. (Grade of recommendation: strong, Level of evidence: moderate)
Q1.  Can we recommend endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adeno-
carcinoma meeting endoscopically estimated tumor size ≤  2 cm and endoscopically suspected mucosal cancer without ulcer?
Patient:  Patients with early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma meeting endo-
scopically estimated tumor size ≤  2 cm and endoscopically suspected mucosal cancer without ulcer
Intervention: Endoscopic resection
Comparator: Gastrectomy with lymph node dissection
Outcome: Survival rate
Study design: RCT or non-RCT
Statement G4: We suggest endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary 
adenocarcinoma with the following endoscopic findings: 1) mucosal cancer > 2 cm without ulcer, or 2) mucosal cancer ≤ 3 cm 
with ulcer. (Grade of recommendation: weak, Level of evidence: moderate)
Q1.  Can we suggest endoscopic resection for early gastric cancer of well or moderately differentiated tubular or papillary adenocarci-
noma with the following endoscopic findings: 1) mucosal cancer >  2 cm without ulcer, or 2) mucosal cancer ≤  3 cm with ulcer?
Patient:  Patients with early gastric cancer of well or moderately differentiated tubular or papillary adenocarcinoma with the following 
endoscopic findings: 1) mucosal cancer >  2 cm without ulcer, or 2) mucosal cancer ≤  3 cm with ulcer
Intervention: Endoscopic resection
Comparator: Gastrectomy with lymph node dissection
Outcome: Survival rate
Study design: RCT or non-RCT
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Statement G5: We suggest endoscopic resection for poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, 
or signet ring cell carcinoma meeting the following endoscopic findings: endoscopically estimated tumor size ≤2 cm, endoscopi-
cally mucosal cancer, and no ulcer in the tumor (Grade of recommendation: weak, Level of evidence: low)
Q1.  Can we suggest endoscopic resection for poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, or signet 
ring cell carcinoma meeting the following endoscopic findings: endoscopically estimated tumor size ≤ 2 cm, endoscopically 
mucosal cancer, and no ulcer in the tumor?
Patient:  Patients with early gastric cancer of poorly differentiated tubular adenocarcinoma, poorly cohesive carcinoma, or signet ring 
cell carcinoma meeting the following endoscopic findings: endoscopically estimated tumor size ≤ 2 cm, endoscopically muco-
sal cancer, and no ulcer in the tumor
Intervention: Endoscopic resection
Comparator: Gastrectomy with lymph node dissection
Outcome: Survival rate
Study design: RCT or non-RCT
Statement G6: We recommend prophylactic hemostasis of visible vessels on the post-resection ulcer caused by endoscopic re-
section of early gastric cancer to lower the risk of delayed bleeding (Grade of recommendation: strong, Level of evidence: low)
Q1.  Can prophylactic hemostasis of visible vessels on the post-resection ulcer caused by endoscopic resection of early gastric can-
cer reduce the risk of delayed bleeding?
Patient: Patients who underwent endoscopic resection for early gastric cancer
Intervention: Prophylactic hemostasis of visible vessels on the post-resection ulcer
Comparator: No prophylactic hemostasis
Outcome: Delayed bleeding
Study design: RCT or non-RCT
Statement G7: We recommend proton pump inhibitors to decrease the risk of symptoms and complications associated with iatro-
genic ulcers caused by endoscopic resection of early gastric cancer. (Grade of recommendation: strong, Level of evidence: high)
Q1.  Can proton pump inhibitors decrease the risk of symptoms and complications associated with iatrogenic ulcers caused by 
endoscopic resection of early gastric cancer?
Patient: Patients who underwent endoscopic resection for early gastric cancer
Intervention: Use of proton pump inhibitors
Comparator: No use of proton pump inhibitors
Outcome: Symptoms and complications associated with iatrogenic ulcers
Study design: RCT or non-RCT
Statement G8: We recommend endoscopic closure as the first treatment option for perforation that occurred during endoscopic 
resection of early gastric cancer. (Grade of recommendation: strong, Level of evidence: low)
Q1. What is the first treatment option for perforation that occurred during endoscopic resection of early gastric cancer?
Patient: Patients with perforation that occurred during endoscopic resection
Intervention: Endoscopic closure
Comparator: Surgery or conservative management
Outcome: Closure rate
Study design: RCT or non-RCT
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Statement G9: We recommend surgical gastrectomy if histopathological evaluation after endoscopic resection of early gastric 
cancer meets the criteria for non-curative resection. An exception applies if cancer invasion is observed at the horizontal resec-
tion margin only. (Grade of recommendation: strong, Level of evidence: moderate) 
Q1.  Is there a difference between observation without surgery and rescue surgery in terms of recurrence and survival in patients 
with early gastric cancer meeting the criteria for non-curative resection (an exception applies if cancer invasion is observed at 
the horizontal resection margin only)? 
Patient:  Patients with early gastric cancer meeting the criteria for non-curative resection (an exception applies if cancer invasion is ob-
served at the horizontal resection margin only)
Intervention: Rescue surgery
Comparator: Observation without surgery
Outcome: Recurrence and survival
Study design: RCT or non-RCT
Statement G10: We recommend additional endoscopic management rather than surgical gastrectomy if histopathological eval-
uation of endoscopically resected early gastric cancer specimen shows positive involvement at the horizontal resection margin 
without any other findings compatible with non-curative resection. (Grade of recommendation: strong, Level of evidence: mod-
erate)
Q1.  Is there a difference between additional endoscopic therapy without surgery and rescue surgery in terms of recurrence and 
survival in patients with early gastric cancer with positive involvement at the horizontal resection margin without any other 
findings compatible with non-curative resection?  
Patient:  Patients with early gastric cancer with positive involvement at the horizontal resection margin without any other findings 
compatible with non-curative resection
Intervention: Additional endoscopic therapy
Comparator: Rescue surgery
Outcome: Recurrence and survival
Study design: RCT or non-RCT
Statement G11: We recommend Helicobacter pylori (H. pylori) eradication treatment after endoscopic resection of early gas-
tric cancer in H. pylori-infected patients. (Grade of recommendation: strong, Level of evidence: high)
Q1.  Can Helicobacter pylori eradication treatment after endoscopic resection of early gastric cancer reduce the metachronous 
gastric cancer in H. pylori-infected patients?
Patient: H. pylori-infected patients after endoscopic resection of early gastric cancer
Intervention: Helicobacter pylori eradication treatment
Comparator: No eradication
Outcome: Incidence of the metachronous gastric cancer
Study design: RCT or non-RCT
Statement G12: We recommend regular surveillance endoscopy every 6–12 months for patients who have had curative endo-
scopic resection of early gastric cancer based on absolute or expanded criteria for early detection of metachronous gastric can-
cer. (Grade of recommendation: strong, Level of evidence: low)
Q1.  Does regular surveillance endoscopy every 6–12 months help the early detection of metachronous gastric cancer in patients 
who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria? 
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Patient: Patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria
Intervention: Surveillance endoscopy every 6–12 months
Comparator: No surveillance endoscopy 
Outcome: Early detection of metachronous gastric cancer
Study design: RCT or non-RCT
Statement G13: We suggest regular abdominopelvic computed tomography scan of 6- to 12-month interval for detection of 
extra-gastric recurrence after curative endoscopic resection of early gastric cancer based on absolute and expanded criteria. 
(Grade of recommendation: weak, Level of evidence: low)
Q1.  Does regular abdominopelvic computed tomography scan every 6–12 months help the detection of extra-gastric recurrence 
in patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria?
Patient: Patients who have had curative endoscopic resection of early gastric cancer based on absolute or expanded criteria
Intervention: Abdominopelvic computed tomography scan every 6–12 months
Comparator: No surveillance computed tomography scan 
Outcome: Detection of extra-gastric recurrence
Study design: RCT or non-RCT
3. Description of PICOs for Early Colorectal Cancer
Statement C1: Poor histologic types (poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcino-
ma), deep submucosal invasion, lymphovascular invasion, and intermediate-to-high–grade tumor budding at the site of deepest 
invasion are risk factors of lymph node metastasis in early colorectal cancer. (Grade of recommendation: strong, Level of evi-
dence: moderate
Q1. Does intramucosal colorectal cancer have the risk of lymph node metastasis?
Patient: Patients who were diagnosed with intramucosal colorectal cancer
Intervention: Not applicable
Comparator: Not applicable
Outcome: Incidence of lymph node metastasis
Study design: RCT or non-RCT
Q2.  Is the risk of lymph node metastasis higher in the deep submucosal invasive colorectal cancer than in the superficial submu-
cosal invasive colorectal cancer?
Patient: Patients who were diagnosed with submucosal colorectal cancer
Intervention: Patients who were diagnosed with deep submucosal colorectal cancer
Comparator: Patients who were diagnosed with superficial submucosal colorectal cancer
Outcome: Incidence of lymph node metastasis
Study design: RCT or non-RCT
Q3.  Is the risk of lymph node metastasis higher in the submucosal invasive colorectal cancer with lymphovascular invasion than 
in the submucosal invasive colorectal cancer without lymphovascular invasion?
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Patient: Patients who were diagnosed with submucosal colorectal cancer
Patient: Patients who were diagnosed with submucosal colorectal cancer with lymphovascular invasion
Comparator: Patients who were diagnosed with submucosal colorectal cancer without lymphovascular invasion
Outcome: Incidence of lymph node metastasis
Study design: RCT or non-RCT
Q4.  Is the risk of lymph node metastasis higher in the submucosal invasive colorectal cancer with tumor budding than in the sub-
mucosal invasive colorectal cancer without tumor budding?
Patient: Patients who were diagnosed with submucosal colorectal cancer
Patient: Patients who were diagnosed with submucosal colorectal cancer with tumor budding
Comparator: Patients who were diagnosed with submucosal colorectal cancer without tumor budding
Outcome: Incidence of lymph node metastasis
Study design: RCT or non-RCT
Q5.  Is the risk of lymph node metastasis higher in the poorly differentiated early colorectal cancer than in the well or moderately 
differentiated early colorectal cancer?
Patient: Patients who were diagnosed with early colorectal cancer
Intervention: Patients who were diagnosed with poorly differentiated early colorectal cancer
Comparator: Patients who were diagnosed with well or moderately differentiated early colorectal cancer
Outcome: Incidence of lymph node metastasis
Study design: RCT or non-RCT
Statement C2: Endoscopic resection of submucosal colorectal cancer with a high risk of lymph node metastasis has a higher re-
currence rate than surgical resection. Therefore, we recommend additional surgery if histological signs after endoscopic resec-
tion suggest a high risk of lymph node metastasis. (Grade of recommendation: strong, Level of evidence: high)
Q1.  Are the recurrence and survival rates different between the endoscopic resection and the surgical resection for the submuco-
sal invasive colorectal cancer with low risk of lymph node metastasis?
Patient: Patients who were diagnosed with submucosal colorectal cancer with low risk of lymph node metastasis
Intervention: Endoscopic resection
Comparator: Surgery
Outcome: Recurrence and/or survival rates
Study design: RCT or non-RCT
Q2.  Are the recurrence and survival rates different between the endoscopic resection and the surgical resection for the submuco-
sal invasive colorectal cancer with high risk of lymph node metastasis?
Patient: Patients who were diagnosed with submucosal colorectal cancer with high risk of lymph node metastasis
Intervention: Endoscopic resection
Comparator: Surgery
Outcome: Recurrence and/or survival rates
Study design: RCT or non-RCT
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Statement C3: We recommend endoscopic assessment of pit patterns and vascular patterns to estimate the depth of submucosal 
invasion before endoscopic resection of early colorectal cancer. (Grade of recommendation: strong, Level of evidence: high)
Q1.  For the diagnosis of suspected/established early colorectal cancer, is narrow band imaging useful to differentiate mucosal/su-
perficial submucosal cancer from deep submucosal cancer compared with white light endoscopy?
Patient: Patients who have suspected or established early colorectal cancer
Intervention: Narrow band imaging
Comparator: White light endoscopy
Outcome: Differentiation of mucosal/superficial submucosal cancer from deep submucosal cancer (diagnostic accuracy)
Study design: RCT or non-RCT
Q2.  For the diagnosis of suspected/established early colorectal cancer, is chromoendoscopy useful to differentiate mucosal/super-
ficial submucosal cancer from deep submucosal cancer compared with white light endoscopy?
Patient: Patients who have suspected or established early colorectal cancer
Intervention: Chromoendoscopy
Comparator: White light endoscopy
Outcome: Differentiation of mucosal/superficial submucosal cancer from deep submucosal cancer (diagnostic accuracy)
Study design: RCT or non-RCT
Q3.  For the diagnosis of suspected/established early colorectal cancer, is magnifying endoscopy useful to differentiate mucosal/ 
superficial submucosal cancer from deep submucosal cancer compared with conventional endoscopy?
Patient: Patients who have suspected or established early colorectal cancer
Intervention: Magnifying endoscopy
Comparator: Conventional (non-magnifying) endoscopy
Outcome: Differentiation of mucosal/superficial submucosal cancer from deep submucosal cancer (diagnostic accuracy)
Study design: RCT or non-RCT
Statement C4. En bloc and histologically complete resection should be achieved for endoscopic treatment of a suspected or es-
tablished early colorectal cancer. We recommend endoscopic submucosal dissection for the treatment of endoscopically resect-
able early colorectal cancer which cannot be resected en bloc using endoscopic mucosal resection technique. (Grade of recom-
mendation: strong, Level of evidence: moderate)
Q1.  Does endoscopic submucosal dissection provide higher en bloc resection rate for suspected or established early colorectal 
cancer than endoscopic mucosal resection or other endoscopic resection techniques?
Patient: Patients who have suspected or established early colorectal cancer
Intervention: Endoscopic submucosal dissection
Comparator: Endoscopic mucosal resection, endoscopic resection techniques other than endoscopic submucosal dissection
Outcome: En bloc resection rate
Study design: RCT or non-RCT
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Supplementary Material 2. Search Flowcharts 
1. Superficial Esophageal Squamous Cell Carcinoma
 Records identified through databases 
searching (n=1,315)
• Ovid-MEDLINE (n=665)







Records after duplicates removed (n=887)
Records screened (n=887)
Records excluded by screening the title 
and abstract (n=870)
Records excluded according to selection 
criteria (n=6)
1. P: Irrelevant population (n=4)
2. I: Irrelevant intervention (n=2)
3. C: Irrelevant comparator (n=0)
4. O: Irrelevant outcome (n=0)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
Full-text articles assessed for eligibility 
(n=17)
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2. Early Gastric Cancer
 Records identified through databases 
searching (n=1,271)
•  Ovid-MEDLINE (n=497)   
•  KoreaMed (n=0)    •  EMBASE (n=676)
•  Cochrane library (n=98)
 Hand searching (n=0)




 Records after duplicates removed (n=857)
 Records screened (n=857)
 Records excluded by screening the title 
and abstract (n=816)
 Records excluded according to selection 
criteria (n=32)
1. P: Irrelevant population (n=9)
2. I: Irrelevant intervention (n=0)
3. C: Irrelevant comparator (n=23)
4. O: Irrelevant outcome (n=0)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=41)
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 Records identified through databases 
searching (n=1,725)
•  Ovid-MEDLINE (n=661)    
•  KoreaMed (n=29)     •  EMBASE (n=819)




absolute indication & 
criteria
 Records after duplicates removed (n=1,671)
 Records screened (n=1,671)
 Records excluded by screening the title 
and abstract (n=1,561)
 Records excluded according to selection 
criteria (n=95)
1. P: Irrelevant population (n=0)
2. I: Irrelevant intervention (n=42)
3. C: Irrelevant comparator (n=22)
4. O: Irrelevant outcome (n=31)
5.  Inappropriate study design  
(a preclinical study) (n=1)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=110)
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 Records identified through databases 
searching (n=1,673)
•  Ovid-MEDLINE (n=689)   
•  KoreaMed (n=61)   •  EMBASE (n=809)




expanded indication & 
criteria about differentiated 
type
 Records after duplicates removed (n=1,059)
 Records screened (n=1,059)
 Records excluded by screening the title 
and abstract (n=909)
 Records excluded according to selection 
criteria (n=141)
1. P: Irrelevant population (n=114)
2. I: Irrelevant intervention (n=14)
3. C: Irrelevant comparator (n=7)
4. O: Irrelevant outcome (n=6)




 Full-text articles assessed for eligibility 
(n=150)
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 Records identified through databases 
searching (n=1,673)
•  Ovid-MEDLINE (n=689)   
•  KoreaMed (n=61)   •  EMBASE (n=809)




expanded indication & 
criteria about 
undifferentiated type
 Records after duplicates removed (n=1,059)
 Records screened (n=1,059)
 Records excluded by screening the title 
and abstract (n=1,014)
 Records excluded according to selection 
criteria (n=41)
1. P: Irrelevant population (n=30)
2. I: Irrelevant intervention (n=4)
3. C: Irrelevant comparator (n=3)
4. O: Irrelevant outcome (n=4)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=45)
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 Records identified through databases 
searching (n=225)
•  Ovid-MEDLINE (n=58)
•  KoreaMed (n=16)   •  EMBASE (n=136)
•  Cochrane library (n=15)
Hand searching (n=0)
Statement G6
Prevention of delayed 
bleeding
 Records after duplicates removed (n=179)
 Records screened (n=179)
 Records excluded by screening the title 
and abstract (n=178)
 Records excluded according to selection 
criteria (n=0)
1. P: Irrelevant population (n=0)
2. I: Irrelevant intervention (n=0)
3. C: Irrelevant comparator (n=0)
4. O: Irrelevant outcome (n=0)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility (n=1)
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 Records identified through databases 
searching (n=331)
•  Ovid-MEDLINE (n=72) 
•  KoreaMed (n=16)  •  EMBASE (n=177)
•  Cochrane library (n=66)
Hand searching (n=0)
Statement G7
Proton pump inhibitor after 
endoscopic resection
 Records after duplicates removed (n=251)
 Records screened (n=251)
 Records excluded by screening the title 
and abstract (n=236)
 Records excluded according to selection 
criteria (n=10)
1. P: Irrelevant population (n=6)
2. I: Irrelevant intervention (n=1)
3. C: Irrelevant comparator (n=0)
4. O: Irrelevant outcome (n=0)
5. Inappropriate study design (n=2)
6. Duplicate (n=0)
7.  Others (a full paper unavailable) 
(n=1)
 Full-text articles assessed for eligibility 
(n=15)
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 Records identified through databases 
searching (n=1,473)
•  Ovid-MEDLINE (n=554)
•  KoreaMed (n=74)    •  EMBASE (n=674)




 Records after duplicates removed (n=999)
 Records screened (n=999)
 Records excluded by screening the title 
and abstract (n=983)
 Records excluded according to selection 
criteria (n=6)
1. P: Irrelevant population (n=3)
2. I: Irrelevant intervention (n=2)
3. C: Irrelevant comparator (n=0)
4. O: Irrelevant outcome (n=0)
5. Inappropriate study design (n=0)
6. Duplicate (n=1)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=16)
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 Records identified through databases 
searching (n=906)
•  Ovid-MEDLINE (n=375) 
•  KoreaMed (n=1)   •  EMBASE (n=424)




except for positive lateral 
margin only
 Records after duplicates removed (n=610)
 Records screened (n=610)
 Records excluded by screening the title 
and abstract (n=584)
 Records excluded according to selection 
criteria (n=12)
1. P: Irrelevant population (n=4)
2. I: Irrelevant intervention (n=8)
3. C: Irrelevant comparator (n=0)
4. O: Irrelevant outcome (n=0)
5. Inappropriate study design (n=0)
6. Duplicate (n=4)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=26)
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 Records identified through databases 
searching (n=1,044)
•  Ovid-MEDLINE (n=434)   
•  KoreaMed (n=5)   •  EMBASE (n=489)




defined as positive lateral 
margin only
 Records after duplicates removed (n=708)
 Records screened (n=708)
 Records excluded by screening the title 
and abstract (n=700)
 Records excluded according to selection 
criteria (n=4)
1. P: Irrelevant population (n=1)
2. I: Irrelevant intervention (n=3)
3. C: Irrelevant comparator (n=0)
4. O: Irrelevant outcome (n=0)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility (n=8)
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 Records identified through databases 
searching (n=850)
•  Ovid-MEDLINE (n=347)   
•  KoreaMed (n=63)    •  EMBASE (n=391)
•  Cochrane library (n=48)
Hand searching (n=1)
Statement G11
Helicobacter pylori eradication 
after endoscopic resection
 Records after duplicates removed (n=570)
 Records screened (n=570)
 Records excluded by screening the title 
and abstract (n=550)
Records excluded according to selection 
criteria (n=13)
1. P: Irrelevant population (n=5)
2. I: Irrelevant intervention (n=0)
3. C: Irrelevant comparator (n=3)
4. O: Irrelevant outcome (n=3)
5. Inappropriate study design (n=0)
6. Duplicate (n=2)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=20)
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searching (n=230)
•  Ovid-MEDLINE (n=62)   
•  KoreaMed (n=3)   •  EMBASE (n=72)





 Records after duplicates removed (n=173)
Records screened (n=173)
 Records excluded by screening the title 
and abstract (n=166)
Records excluded according to selection 
criteria (n=0)
1. P: Irrelevant population (n=0)
2. I: Irrelevant intervention (n=0)
3. C: Irrelevant comparator (n=0)
4. O: Irrelevant outcome (n=0)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility (n=7)
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searching (n=563)
•  Ovid-MEDLINE (n=172)    
•  KoreaMed (n=4)    •  EMBASE (n=327)





 Records after duplicates removed (n=416)
 Records screened (n=416)
 Records excluded by screening the title 
and abstract (n=410)
Records excluded according to selection 
criteria (n=2)
1. P: Irrelevant population (n=0)
2. I: Irrelevant intervention (n=0)
3. C: Irrelevant comparator (n=2)
4. O: Irrelevant outcome (n=0)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility (n=6)
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3. Early Colorectal Cancer
 Records identified through databases 
searching (n=705)
•  Ovid-MEDLINE (n=153)   
•  KoreaMed (n=293)   •  EMBASE (n=226)
•  Cochrane library (n=33)
Hand searching (n=0)
Statement C1
Lymph node metastasis in 
intramucosal colorectal 
cancer
 Records after duplicates removed (n=661)
Records screened (n=661)
 Records excluded by screening the title 
and abstract (n=618)
 Records excluded according to selection 
criteria (n=21)
1. P: Irrelevant population (n=5)
2. I: Irrelevant intervention (n=5)
3. C: Irrelevant comparator (n=3)
4. O: Irrelevant outcome (n=7)
5. Inappropriate study design (n=0)
6. Duplicate (n=1)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=43)
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 Records identified through databases 
searching (n=672)
•  Ovid-MEDLINE (n=112)   
•  KoreaMed (n=293)    •  EMBASE (n=252)
•  Cochrane library (n=15)
Hand searching (n=0)
Statement C1
Association of deep 
submucosal invasive cancer 
or lymphovascular invasion 
with lymph node metastasis
 Records after duplicates removed (n=576)
Records screened (n=576)
 Records excluded by screening the title 
and abstract (n=544)
 Records excluded according to selection 
criteria (n=18)
1. P: Irrelevant population (n=10)
2. I: Irrelevant intervention (n=2)
3. C: Irrelevant comparator (n=0)
4. O: Irrelevant outcome (n=6)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=32)
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 Records identified through databases 
searching (n=407)
•  Ovid-MEDLINE (n=61)   
•  KoreaMed (n=293)   •  EMBASE (n=47)
•  Cochrane library (n=6)
Hand searching (n=0)
Statement C1
Association of tumor budding 
with lymph node metastasis
 Records after duplicates removed (n=379)
Records screened (n=379)
 Records excluded by screening the title 
and abstract (n=340)
 Records excluded according to selection 
criteria (n=26)
1. P: Irrelevant population (n=12)
2. I: Irrelevant intervention (n=5)
3. C: Irrelevant comparator (n=0)
4. O: Irrelevant outcome (n=9)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=39)
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 Records identified through databases 
searching (n=467)
•  Ovid-MEDLINE (n=38)   
•  KoreaMed (n=293)   •  EMBASE (n=129)
•  Cochrane library (n=7)
Hand searching (n=0)
Statement C1
Association of histologic 
differentiation with lymph 
node metastasis
 Records after duplicates removed (n=427)
Records screened (n=427)
 Records excluded by screening the title 
and abstract (n=397)
 Records excluded according to selection 
criteria (n=17)
1. P: Irrelevant population (n=6)
2. I: Irrelevant intervention (n=6)
3. C: Irrelevant comparator (n=1)
4. O: Irrelevant outcome (n=4)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=30)
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 Records identified through databases 
searching (n=1,718)
•  Ovid-MEDLINE (n=489)   
•  KoreaMed (n=44)   •  EMBASE (n=892)
•  Cochrane library (n=293)
Hand searching (n=0)
Statement C2
Association of lymph 
node metastasis risk with 
recurrence and survival after 
endoscopic resection
 Records after duplicates removed (n=1,310)
Records screened (n=1,310)
 Records excluded by screening the title 
and abstract (n=1,101)
 Records excluded according to selection 
criteria (n=199)
1. P: Irrelevant population (n=28)
2. I: Irrelevant intervention (n=151)
3. C: Irrelevant comparator (n=16)
4. O: Irrelevant outcome (n=4)
5. 0 Inappropriate study design (n=0)
6. 0 Duplicate (n=0)
7. 0 Others (n=0)
 Full-text articles assessed for eligibility 
(n=209)
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 Records identified through databases 
searching (n=223)
•  Ovid-MEDLINE (n=65)   
•  KoreaMed (n=57)    •  EMBASE (n=72)
•  Cochrane library (n=29)
Hand searching (n=0)
Statement C3
Endoscopic estimation of 
histology: narrow band 
imaging vs. white light 
endoscopy in early colorectal 
cancer
 Records after duplicates removed (n=160)
Records screened (n=160)
 Records excluded by screening the title 
and abstract (n=121)
 Records excluded according to selection 
criteria (n=38)
1. P: Irrelevant population (n=16)
2. I: Irrelevant intervention (n=11)
3. C: Irrelevant comparator (n=3)
4. O: Irrelevant outcome (n=7)
5.  Inappropriate study design  
(n=1, a preclinical study)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=39)






















https://doi.org/10.5217/ir.2020.00020  • Intest Res 2021;19(2):127-157
www.irjournal.org
<doi> • <doi 1>
 Records identified through databases 
searching (n=227)
•  Ovid-MEDLINE (n=71)   
•  KoreaMed (n=57)   •  EMBASE (n=69)
•  Cochrane library (n=30)
Hand searching (n=0)
Statement C3
Endoscopic estimation of 
histology: chromoendoscopy 
vs. white light endoscopy in 
early colorectal cancer
 Records after duplicates removed (n=166)
Records screened (n=166)
 Records excluded by screening the title 
and abstract (n=127)
 Records excluded according to selection 
criteria (n=38)
1. P: Irrelevant population (n=16)
2. I: Irrelevant intervention (n=8)
3. C: Irrelevant comparator (n=7)
4. O: Irrelevant outcome (n=6)
5.  Inappropriate study design  
(n=1, a preclinical study)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=39)
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 Records identified through databases 
searching (n=508)
•  Ovid-MEDLINE (n=171)   
•  KoreaMed (n=57)    •  EMBASE (n=234)




of histology: magnified 
endoscopy vs. conventional 
endoscopy in early colorectal 
cancer
 Records after duplicates removed (n=361)
Records screened (n=361)
 Records excluded by screening the title 
and abstract (n=246)
 Records excluded according to selection 
criteria (n=99)
1. P: Irrelevant population (n=28)
2. I: Irrelevant intervention (n=19)
3. C: Irrelevant comparator (n=19)
4. O: Irrelevant outcome (n=19)
5. Inappropriate study design (n=0)
6. Duplicate (n=0)
7. Others (n=0)
 Full-text articles assessed for eligibility 
(n=115)
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 Records identified through databases 
searching (n=844)
•  Ovid-MEDLINE (n=135) 
•  KoreaMed (n=90)     •  EMBASE (n=382)
•  Cochrane library (n=237)
Hand searching (n=0)
Statement C4
Endoscopic treatment of 
early colorectal cancer
 Records after duplicates removed (n=710)
Records screened (n=710)
 Records excluded by screening the title 
and abstract (n=337)
 Records excluded according to selection 
criteria (n=366)
1. P: Irrelevant population (n=110)
2. I: Irrelevant intervention (n=42)
3. C: Irrelevant comparator (n=209)
4. O: Irrelevant outcome (n=1)
5.  Inappropriate study design  
(n=1, a preclinical study)
6. Duplicate (n=2)
7. Others (n=1, a full paper unavailable)
 Full-text articles assessed for eligibility 
(n=373)
 Studies finally included (n=7)
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